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ABSTRACT

THE EVOLUTION OF PLATELET RESPONSES TO COLLAGEN UNDER
CONDITIONS OF HEMODYNAMIC FLOW

Author: Alec A. Schmaier
Supervisor: Mark L. Kahn

Collagen activates platelets through the immune-type GPVI receptor, but the mechanism
by which this receptor has adapted to function in platelets under conditions of rapid blood
flow is unclear. Additionally, it is unknown if responses to collagen are conserved in
nucleated thrombocytes found in non-mammalian vertebrates, which do not express
GPVI. Here we show that the GPVI proline-rich domain accelerates GPVI signaling
kinetics and is required for maximal adhesion to collagen under flow. The proline-rich
domain accelerates signaling through binding and directly activating the Src-family
kinase Lyn. Chicken thrombocytes are potently activated by collagen but do not form 3dimensional aggregates under arterial flow conditions, a profound contrast to platelet
function. Despite selective expression of most platelet-specific genes, thrombocytes
contain a significantly lower density of !2b"3 integrin on the cell surface. These studies
identify a novel molecular mechanism by which GPVI accelerates immune signaling
kinetics and demonstrate partial conservation of hemostatic cell responses to collagen
under flow.

v

Table of Contents
Acknowledgements ............................................................................................................ ii
Abstract .............................................................................................................................. v
Table of Contents .............................................................................................................. vi
List of Tables .................................................................................................................... ix
List of Figures .................................................................................................................... x
Chapter 1—Introduction ..................................................................................................... 1
Summary ............................................................................................................................. 1
Overview of platelets and collagen in hemostasis and thrombosis .............................. 1
Platelets in human cardiovascular disease ................................................................... 2
Platelet and thrombocyte biology ................................................................................ 3
Effects of blood rheology on platelet interaction with the vessel wall ....................... 4
Platelet activation ......................................................................................................... 5
Platelet responses to collagen under arterial flow conditions ...................................... 6
GPVI is a platelet receptor for collagen ....................................................................... 7
!2"1 integrin is a high-affinity collagen receptor ........................................................ 8
GPVI activates platelets through an immune-receptor signaling pathway .................. 9
GPVI is required for collagen-induced platelet activation ......................................... 10
The role of GPVI in models of thrombosis and hemostasis ....................................... 11
The role of GPVI in human cardiovascular disease ................................................... 12
A model for platelet responses to collagen under flow and the role of GPVI ........... 13
Conclusions and outstanding questions ...................................................................... 14
Chapter 2—Molecular priming of Lyn by GPVI enables an immune receptor to adopt a
hemostatic role ................................................................................................................. 22
Summary .................................................................................................................... 22
Introduction ................................................................................................................ 23
Results ........................................................................................................................ 26
GPVI receptors lacking the intracellular PRD are expressed on mouse platelets
through retroviral transduction of hematopoietic progenitors ............................. 26
Loss of the GPVI PRD does not alter sustained GPVI signaling in platelets ...... 27
The GPVI PRD is required for rapid platelet activation by GPVI ...................... 28
P-selectin expression is an appropriate readout for measuring sustained GPVIinduced activation, whereas fibrinogen binding is preferable for measuring
GPVI signaling kinetics ....................................................................................... 29
Loss of the PRD delays proximal GPVI signal transduction in RBL-2H3
cells ...................................................................................................................... 29
The GPVI PRD is required for efficient platelet adhesion to collagen
under flow ............................................................................................................ 30
The GPVI PRD preferentially binds the SH3 domains of Lyn and Hck ............. 32
GPVI PRD binding directly activates the Lyn and Hck kinases ......................... 34
GPVI-bound Lyn is held in the active state in resting platelets ........................... 35
vi

Lyn-deficient platelets exhibit the delayed GPVI receptor signaling and
defective adhesion to collagen under flow characteristic of PD GPVI
platelets ................................................................................................................ 36
Discussion .................................................................................................................. 38
Materials and methods ............................................................................................... 43
Chapter 3—In contrast to mammalian platelets, avian thrombocytes do not form
aggregates on collagen under arterial flow conditions ..................................................... 85
Summary .................................................................................................................... 85
Introduction ................................................................................................................ 86
Results ........................................................................................................................ 90
Chicken thrombocytes specifically express genes associated with platelet
function ................................................................................................................ 90
Chicken thrombocytes are strongly activated by thrombin and collagen ............ 91
Collagen-induced signaling in the thrombocyte requires Src-kinases and Syk ... 93
Thrombocytes do not form aggregates on a collagen surface under arterial
shear conditions .................................................................................................... 93
Thrombocytes are fully activated despite a lack of aggregate formation under
hemodynamic flow ............................................................................................... 96
Pharmacologic inhibition of integrin function or collagen signaling decreases
thrombocyte adhesion to collagen under flow ..................................................... 97
Thrombocytes express fewer !2b"3 integrin receptors than do platelets and
are not affected by !2b"3 inhibition during adhesion to collagen under flow ..... 98
Platelets, but not thrombocytes, utilize ADP signaling to enhance adhesion
and aggregate formation under hemodynamic flow ............................................ 99
Discussion ................................................................................................................ 101
Materials and methods ............................................................................................. 109
Supplemental movie legends ................................................................................... 135
Chapter 4—Conclusions and future directions .............................................................. 136
Summary .................................................................................................................. 136
Use of immune-type receptor signaling to activate hemostatic cells in response
to collagen ................................................................................................................ 137
Future directions for GPVI and thrombocyte research ............................................ 138
Is GPVI / FcR# embedded in the cell membrane to prevent constitutive
signaling from bound and activated Lyn kinase? .............................................. 139
What are the selective roles of Lyn and Fyn kinase in the initial events
of GPVI signaling? ............................................................................................ 140
What is the receptor responsible for activating thrombocytes in response to
collagen? ............................................................................................................ 141
How is GPVI function conserved among mammalian species? ........................ 142
If thrombocytes do not form aggregates on collagen under arterial flow
conditions, how does cellular hemostasis function in avian species? ............... 144
vii

Concluding remarks: The evolution of platelet responses to collagen under
conditions of hemodynamic flow ....................................................................... 146
Materials and methods ............................................................................................. 149
References ...................................................................................................................... 155

viii

List of Tables
Table 2-I. The GPVI cytoplasmic tail preferentially binds the SFKs Lyn and Hck ....... 74
Table 3-I. Detection of platelet-specific gene expression in thrombocytes by
transcriptional profiling ................................................................................................. 118

ix

List of Figures
Figure 1-1. A model for coagulation system and platelet activation following
vascular injury in flowing blood ...................................................................................... 17
Figure 1-2. GPVI signal transduction ............................................................................. 19
Figure 1-3. The role of GPVI in platelet responses to collagen under flow ................... 21
Figure 2-1. Expression of wild-type GPVI receptors and GPVI receptors lacking the
intracellular PRD in GPVI-deficient mouse platelets using retroviral vectors ................ 56
Figure 2-2. Loss of the GPVI PRD does not alter sustained GPVI receptor signaling
in platelets ........................................................................................................................ 60
Figure 2-3. The intracellular PRD is required for rapid platelet activation by GPVI
receptors ........................................................................................................................... 62
Figure 2-4. Time course analysis of P-selectin expression and fibrinogen binding
following convulxin stimulation in wild-type platelets ................................................... 64
Figure 2-5. PD GPVI receptors exhibit delayed Syk phosphorylation and calcium
signaling ........................................................................................................................... 66
Figure 2-6. Tracking rolling and adhesion of GFP+/GPVI+ platelets to collagen
under flow ........................................................................................................................ 68
Figure 2-7. The GPVI PRD is required for efficient platelet adhesion to collagen
under flow ........................................................................................................................ 70
Figure 2-8. The GPVI PRD preferentially binds the SH3 domains of the SFKs
Lyn and Hck .................................................................................................................... 72
Figure 2-9. GPVI directly activates Lyn and Hck in a PRD-dependent manner ............ 75
Figure 2-10. GPVI-bound Lyn is held in the active state in unstimulated platelets ....... 77
Figure 2-11. Lyn- and Fyn-deficient platelet activation following convulxin
stimulation ....................................................................................................................... 79
Figure 2-12. Lyn-deficient platelets exhibit defective adhesion to collagen
under flow ........................................................................................................................ 82
Figure 2-13. Priming of Lyn by the GPVI PRD drives rapid signal transduction
following receptor ligation ............................................................................................... 84
Figure 3-1. Analysis of chicken plasma preps by flow cytometry ............................... 116
Figure 3-2. Activation of chicken thrombocytes by collagen and thrombin ................ 119
Figure 3-3. PP2 and piceatannol inhibit collagen-induced 5-HT secretion in
thrombocytes in a dose-dependent manner ................................................................... 122
Figure 3-4. Chicken collagen type-I and –III coated on glass slides ............................ 124
Figure 3-5. Thrombocytes cover less surface area and fail to form aggregates during
adhesion to collagen under whole blood flow ............................................................... 125
Figure 3-6. Chicken thrombocytes do not form aggregates after extended flow
of whole blood ............................................................................................................... 128
Figure 3-7. Scanning electron microscopy of platelets and thrombocytes following
adhesion to collagen under whole blood flow ............................................................... 129

x

Figure 3-8. Thrombocyte adhesion to collagen under flow is sensitive to Src-family
kinase inhibition ............................................................................................................. 131
Figure 3-9. Thrombocytes express fewer !2b"3 integrin receptors than do platelets
and are not affected by !2b"3 inhibition during adhesion to collagen under flow ......... 132
Figure 3-10. The effect of P2Y12 inhibition on platelet and thrombocyte adhesion to
collagen under flow ........................................................................................................ 134
Figure 4-1. The response of echidna and opposum platelets to GPVI ligands ............. 150
Figure 4-2. Alignment of GPVI sequences from opossum, mouse, and human ........... 153

xi

Chapter 1—Introduction: Platelet responses to collagen and the role of GPVI

Summary
Platelets are essential for normal hemostasis, but their activation also underlies the
disease mechanisms of heart attack and stroke. This introductory chapter focuses on the
role of collagen in platelet-mediated thrombus formation following vessel injury and the
role of GPVI as the primary activator of platelets in response to collagen.

Overview of platelets and collagen in hemostasis and thrombosis
Warm-blooded organisms, including mammals and birds, circulate blood at high
pressures to perfuse organs at a level commensurate with tissue metabolism. Since an
adequate amount of blood perfusion is required to maintain tissue oxygenation and
removal of CO2 and waste products, highly evolved mechanisms exist within each
species to prevent excess blood loss. Hemostasis, the cessation of bleeding, involves the
coordination of both a cellular component made up of platelets and a plasma protein
system consisting of coagulation factors present in circulating blood (Fig. 1-1)1. In its
extreme form, excess hemostasis leads to thrombosis, the occlusion of a blood vessel,
which is physiologic in preventing catastrophic hemorrhage following traumatic vessel
injury but is pathophysiologic during injury in diseased arteries, leading to acute
myocardial infarction and stroke.
Blood vessel injury exposes pro-thrombotic material, such as tissue factor and
collagen, to circulating blood. Tissue factor exposure leads to the generation of thrombin
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through coagulation cascade activation, and thrombin activates platelets and cleaves
fibrinogen into fibrin to promote clot formation. Collagen is the major protein
component of the extracellular matrix (ECM) that lies beneath the endothelial cell layer
lining the blood vessels. Exposure of subendothelial collagen initiates two processes: (1)
rapid platelet activation and (2) factor XII autoactivation with factor XIa formation
leading to thrombin formation2. Both activities, along with thrombin generation,
contribute to the formation of a platelet plug, resulting in further coagulant activity and
the production of a fibrin-containing thrombus. Determining how platelets adhere and
are activated by exposure of ECM components is essential to understanding the
pathogenesis of acute thrombotic cardiovascular disease.

Platelets in human cardiovascular disease
The primary physiologic function of platelets is to stop hemorrhage after tissue trauma
and vessel injury and to initiate an inflammatory response to repair the injury. The
importance of platelets in hemostasis is evident by the increased risk of bleeding in
patients who are thrombocytopenic, taking anti-platelet agents such as aspirin or
clopidogrel, or lack critical platelet receptors such as in Glanzmann’s thrombasthenia or
Bernard-Soulier syndrome. However, platelets have a causal role in the pathologic
thrombosis of cardiovascular disease. Cardiovascular disease, both coronary and
cerebrovascular, is the leading cause of death in the United States and worldwide and, as
a chronic condition, is predominantly associated with atherosclerosis3. Coronary
atherosclerosis is unquestionably the leading cause of acute coronary syndromes,
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including unstable angina, acute myocardial infarction and sudden cardiac death4. The
primary event mediating athero-thrombosis is believed to be rupture of an unstable, nonstenotic atherosclerotic plaque, which exposes pro-thrombotic material and leads to
platelet-mediated occlusive thrombus formation5,6. A major goal in the study of platelet
biology is aimed at better understanding the mechanisms underlying acute thrombosis in
the setting of atherosclerotic disease. Anti-platelet agents that target major components
of platelet function are first-line in treatment of cardiovascular disease. However, the
association of these drugs with bleeding complications underlies the importance for
development of more refined platelet inhibitors that specifically target athero-thrombotic
pathophysiology without interfering with physiologic hemostasis.

Platelet and thrombocyte biology
Platelets are uniquely suited to serve as hemostatic cells in mammalian physiology. They
are the smallest cell type found in circulating blood, averaging a diameter of 2.0 to 3.0
µm and a thickness of 0.5 µm, and they lack a nucleus7. Platelets are produced from
megakaryocytes, large polyploid cells found primarily in the bone marrow, by protrusion
of long, beaded cytoplasmic extensions called proplatelets into the bone marrow
sinusoids where they can be released to enter the bloodstream8. Once in the blood,
platelets may circulate for a lifespan of 7-10 days before being destroyed by the
reticuloendothelial system of the spleen. Platelets are extremely numerous in the
circulation—a normal platelet count is 150-450,000 per µL in humans and can be greater
than 1 x 106 per µL in mice—making them excellent surveyors of vascular integrity,
3

ready to respond immediately, in large numbers, at the site of vessel injury. However,
platelets are not found in all warm-blooded species with a high-pressure vascular system.
Platelets are unique to mammals, whereas non-mammalian vertebrates contain
thrombocytes—larger, nucleated cells, tenfold less numerous than platelets, that are
believed to serve an analogous hemostatic function. Much less is known about the
biology of thrombocytes, their protein expression, or their function in vivo. Chapter 3
will compare the biology of mammalian platelets to that of avian thrombocytes to
determine if responses to collagen in cellular hemostasis are conserved throughout
evolution.

Effects of blood rheology on platelet interaction with the vessel wall
Blood rheology is an important component for platelet activation under arterial
conditions. Blood flow is considered to be laminar, meaning that layers of blood pass
each other at different velocities, resulting in a flow gradient where the velocity is highest
in the middle of the vessel and almost zero at the vessel wall9. The flow velocity gradient
is highest near the edge of vessel and very small near the middle of the vessel. As a
result of this velocity gradient, shear rate (!), the rate at which flow velocity changes
(expressed as s-1), and shear stress ("), the tangential force per unit area exerted in the
direction of flow (expressed as dynes/cm2), are greater at the vessel wall than in the
middle of the vessel. Areas of increased shear rate and shear stress, such as the edge of
the vessel wall, have a positive effect on platelet adhesion9,10.
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The shear rates are very low in large vessels but increase to 1500 s-1 in small
arteries and can increase dramatically to 40,000 s-1 in stenosed arteries11. This increased
vessel shear rate in the setting of atherosclerosis is certainly an important factor
contributing to pathologic activation and adhesion of platelets. The presence of red blood
cells, which normally occupy 38-48% of blood volume, also has a profound effect on
platelet distribution within a vessel. As shear rates increase, red blood cells are found
toward the center of the vessel, and the smaller platelets are pushed toward the vessel
edge, further facilitating platelet interaction with the vessel wall12. Increased blood
viscosity also exerts a positive effect on platelet deposition13. The higher shear rate and
shear stress of stenosed arteries and the role of blood viscosity are all contributing factors
in the setting of arterio-thrombotic cardiovascular disease. Chapters 2 and 3 will examine
the adhesion and aggregation of platelets in response to collagen, using flow chambers
that reproduce arterial flow conditions.

Platelet activation
Several aspects of platelet cell biology allow for an efficient response to vascular injury.
Upon encountering subendothelial ECM components such as von Willebrand Factor
(vWF) or collagen and being exposed to soluble activators such as thrombin, adenosine
diphosphate (ADP), serotonin (5-hydroxytryptamine or 5-HT), or thromboxane (TXA2),
platelets undergo a rapid and coordinated process of shape change associated with the
transition from a quiescent to an activated state. Platelet activation is associated with cell
spreading, which allows platelets to flatten and cover a damaged surface through
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lamellipodia formation. Activation and recruitment of additional platelets is facilitated
by filopodia extension. These spreading processes involve dynamic reorganization of the
actin cytoskeleton and expansion of platelet surface area through recruitment of extensive
membrane infoldings called the open canalicular system. The ability of platelets to
rapidly change from a discoid shape to a flattened, spread shape is crucial to their
functioning effectively as hemostatic cells. In Chapter 3, the ability of avian
thrombocytes to perform these spreading processes will be examined to determine if this
element of cellular hemostasis is conserved through evolution.

Platelet responses to collagen under arterial flow conditions
Thrombus formation at the sites of arterial injury requires the coordinated process of
platelet adhesion, activation, degranulation, and aggregation. These events occur within
seconds in the high-flow environment of the arterial system, and an individual platelet
has only nano- to microseconds during which to interact with a site of vascular injury.
Fibrous collagens, especially types I and III, constitute up to 40% of the proteins of the
vessel wall, and these are the major ECM proteins that support robust platelet adhesion
and activation14. Along with thrombin generation, collagen exposure to the rolling
platelet is a primary event in platelet-mediated thrombosis (Fig 1-1). Platelets express
two receptors, glycoprotein VI (GPVI) and the #2$1 integrin, which have significant roles
in the interaction of platelets with collagen15,16. Chapter 2 will discuss a unique element
of GPVI signal transduction. Chapter 3 will consider collagen-induced cellular
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hemostasis in the chicken, which does not have platelets but instead has larger, nucleated
thrombocytes that do not express GPVI.

GPVI is a platelet receptor for collagen
The role of GPVI as a platelet collagen receptor was initially based on the observation
that patients deficient in this protein exhibit a bleeding tendency and defective platelet
aggregation in response to collagen15,17. GPVI is mapped to a gene cluster known as the
leukocyte receptor complex (LRC, on chromosome 19 in humans) which includes killerinhibitory receptors (KIRs), leukocyte Ig-like receptors (LILRs), and the IgA receptor
Fc#RI, among other Ig-domain containing receptors18,19. As an LRC gene, GPVI is a
member of the paired immunoglobulin (Ig) receptor superfamily but is expressed
exclusively on platelets and megakaryocytes20. The closest homolog of GPVI is Fc#RI,
expressed on neutrophils, eosinophils, monocyte/macrophages, and interstitial dendritic
cells, and both GPVI and Fc#RI require association with the adaptor protein FcR! via
transmembrane arginines on the receptor for normal surface expression and signal
transduction18,21,22.
The absence of 11 consecutive amino acids in the sequence of GPVI, compared to
that of Fc#RI, creates a shallow hydrophobic groove on the surface of the distal Ig
domain that forms a putative collagen-binding site23. GPVI is believed to exist as a dimer
where two GPVI Ig domains form parallel collagen binding grooves23,24. GPVI only
recognizes fibrillar, not monomeric, collagen and binds to glycine-prolinehydroxyproline (GPO) triplets that constitute about 10% of the primary sequence of
7

collagens type I and III25. While the heterogeneity of collagen ligand makes it difficult to
determine an absolute affinity, GPVI appears to be a relatively low-affinity collagen
receptor, with the estimated Kd of GPVI and collagen being 57 µM24,26. Additionally,
GPVI is capable of binding and activating platelets in response to laminin, another
subendothelial basement membrane protein that adopts a similar triple helical
structure26,27. This finding suggests that GPVI may function less as a highly specific
collagen receptor and more as a sensor for the presence of ECM proteins. Chapter 3 will
consider whether chicken thrombocytes express collagen receptors capable of signal
transduction and thrombocyte activation.
The study of GPVI has been aided by the existence of high-affinity GPVI-specific
ligands that readily induce GPVI clustering on the cell surface and subsequent platelet
activation. Synthetic collagen-related peptide (CRP) contains multiple runs of the GPO
motif cross-linked to recapitulate the quaternary structure of collagen28,29, and the C-type
lectin convulxin (CVX), isolated from the venom of the crotalus durissus terrificus,
forms a hexamer that binds the proximal Ig domain of the receptor30.

# 2$ 1 integrin is a high-affinity collagen receptor
The #2$1 integrin was the first collagen receptor to be identified on platelets and is
expressed at copy numbers roughly equal to that of GPVI31. The #2 subunit of this
integrin contains an I (“inserted”) domain which binds collagen with relatively high
affinity compared to GPVI (Kd = 35-90 nM) in a Mg2+-dependent manner. #2$1
recognizes the Gly-Phe-[hydroxy]Pro-Gly-Glu-Arg (GFOGER) motif, found in various
8

collagen subtypes but constituting only about 0.02% of the primary collagen sequence32.
A role for #2$1 in platelet activation has not been well established, although the integrin
has the potential to transduce signal that could function in concert with GPVI signaling3335

. However, collagen-induced platelet activation responses such as aggregation,

degranulation, and fibrinogen binding are almost completely normal in #2$1-deficient
platelets34,36.
Like the well-characterized #IIb$3 platelet integrin, one factor complicating the
study of #2$1 is its strict dependence on “inside-out” signals to activate the integrin from
a low- to high-affinity state where it is capable of binding ligand37,38. Platelet integrins,
including #2$1, can be activated by G-protein coupled agonists such as thrombin and
ADP. However, the absolute dependence on GPVI signaling in ex vivo collagen assays
suggests that when collagen is the sole activator, GPVI is required to stimulate #2$1
before the integrin is able to bind ligand. Regardless of how it is activated, #2$1 is
required for firm adhesion to collagen under hemodynamic flow, serving as a highaffinity collagen receptor that, once activated, arrests platelet translocation along the
vessel wall39-41. This dissertation will not focus on #2$1 directly, but it is important to
consider its role in platelet adhesion to collagen under flow, which will be discussed in
depth in Chapters 2 and 3.

GPVI activates platelets through an immune-receptor signaling pathway
Structure-function studies in platelets and cell lines have established that GPVI signal
transduction mechanisms are analogous to immune receptor pathways seen in other
9

hematopoietic cells. Like other immune cell receptors, GPVI is believed to exist on the
membrane within lipid rafts, and ligands that induce receptor clustering initiate GPVI
signal transduction through colocalization of effector proteins42,43. Upon receptor
ligation, GPVI signal transduction is initiated as follows: the GPVI-bound FcR! adaptor,
which contains an immunoreceptor tyrosine-based activation motif (ITAM), is
phosphorylated by membrane-bound Src-family kinases (SFKs), specifically Lyn and
Fyn, leading to recruitment and activation of the tyrosine kinase Syk (Fig. 1-2). Syk
activation initiates assembly of a signaling complex via phosphorylation of the adaptor
proteins linker for activated T-cells (LAT), Gads, and Src homology (SH)2 domaincontaining leukocyte phosphoprotein of 76 kD (Slp-76) (Fig. 1-2). Assembly of this
signaling complex leads to activation of phospholipase C (PLC!2). PLC!2 cleavage of
phosphatidylinositol 4,5-bisphosphate (PIP2) culminates in activation of protein kinase C
(PKC) and generation of Ca2+ flux, a common endpoint for platelet activating signals
(Fig. 1-2)16,22,44-53. GPVI also employs signal transduction mechanisms that are unique
compared to other FcR!-coupled immune receptors, and these observations will be
described in Chapter 2.

GPVI is required for collagen-induced platelet activation
Genetic and pharmacologic studies have demonstrated that GPVI is both necessary and
sufficient to activate platelets in response to collagen. GPVI- or FcR!-deficient mouse
platelets do not aggregate, degranulate, or activate integrins in response to collagen36,54,55.
Deficiency of GPVI signaling effectors such as SFKs Lyn and Fyn, Syk, LAT, Slp-76,
10

and PLC!2 also abolishes collagen-induced platelet activation47,48,50,51,56,57. In the
absence of the other major platelet collagen receptor, #2$1, discussed later, GPVI is
capable of inducing normal platelet activation in response to collagen34,36. Additionally,
expression of GPVI in cell line systems that express immune-type signaling effector
molecules is sufficient for collagen-induced signal transduction58,59.
Using various blood perfusion chamber approaches for both mouse and human
platelets, GPVI-FcR! has been shown to be crucial for platelet adhesion to collagen under
arterial shear conditions, an ex vivo response that most closely represents that function of
platelets in vivo36,40,60-62. Chapter 2 will address whether and how GPVI has adapted this
immune receptor signaling pathway to accelerate platelet activation kinetics required for
adhesion to collagen under flow.

The role of GPVI in models of thrombosis and hemostasis
Atherosclerosis involves pathological changes to the vessel wall, such as an increase in
ECM deposition, especially that of collagen63. Prothrombotic material exposed following
plaque rupture induces strong platelet activation that is GPVI-dependent, thereby
suggesting a role for GPVI in athero-thrombotic disease64,65. Studies in the mouse aimed
at establishing the importance of GPVI in mediating arterial thrombosis have produced
varying results, likely due to the different types of arterial injuries produced by
experimental models. GPVI deficiency has little effect on thrombosis following laser
injury to the cremasteric muscle arteriole, believed to be due to the fact that thrombosis in
this model is thrombin-dependent and subendothelial collagen is not exposed66-68.
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However, more extensive injury model systems can be employed, such as a ferric
chloride (FeCl3)-induced injury to the cremasteric arterioles or mesenteric and carotid
arteries, where reactive oxygen species destroy the endothelium and expose basement
membrane collagen69. In more substantial injury models, including FeCl3, GPVI-induced
platelet activation is a requirement for thrombosis67,70-72. Tail bleeding times of GPVIdeficient mice are either normal or only slightly prolonged, however, suggesting that
GPVI may not be essential for normal platelet function following minor trauma54,55,73,74.
The role of GPVI in hemostasis and thrombosis in vivo will not be directly examined in
this work. However, the mechanism by which GPVI is able to rapidly activate platelets
under hemodynamic flow conditions, a requirement for normal hemostasis and
pathologic arterial thrombosis, which will be considered in Chapter 2. Chapter 3 will
address whether this fundamental mechanism of thrombus formation following collagen
exposure is present in organisms that contain thrombocytes instead of platelets.

The role of GPVI in human cardiovascular disease
Increased expression of GPVI or #2$1 on platelets is associated with increased
risk of athero-thrombotic disease and implicated as a negative prognostic biomarker in
patients with cardiovascular disease75-80. It has been difficult to determine a role for
GPVI in hemostasis in humans since most cases of GPVI deficiency are seen in patients
with anti-GPVI auto-antibody production associated with some degree of immune
thrombocytopenia81. Isolated deficiency of GPVI by compound heterozygosity, although
extremely rare, is associated with only a mild bleeding diathesis82,83. Together, the
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finding that GPVI deficiency confers a protection from thrombosis, while not producing a
bleeding phenotype, has generated interest in pharmacologic targeting of GPVI for
therapeutic potential. GPVI inhibition may help prevent the formation of pathologic
thrombi associated with the coronary and cerebral arteries70,84. Continued investigation
of GPVI and collagen-induced cellular hemostasis as a fundamental mechanism of
arterio-thrombotic disease and as a potential therapeutic target in humans is warranted.

A model for platelet responses to collagen under flow and the role of GPVI
Extensive work has demonstrated that, on a collagen-coated surface under hemodynamic
flow in the absence of thrombin activity, platelets will translocate, or “roll,” along
collagen, activate, firmly adhere, and form 3-dimensional aggregates85. This process is
initiated by platelet receptor GPIba/IX/V contact with collagen-bound vWF that is
linearized by high shear forces on the vessel wall10,86. The platelet-vWF interaction
results in platelet translocation along the vessel edge and allows GPVI to interact with
collagen and transduce signals that activate the platelet (Fig. 1-3). GPVI binds collagen
with low affinity and is therefore unlikely to directly mediate firm adhesion to collagen.
However, GPVI signaling through FcR!, Syk, Slp-76, and PLC!2 is crucial for activation
of high-affinity integrins, such as #2$1, which mediate firm adhesion to collagen, and
#2b$3, which binds fibrinogen in plasma to cross-link platelets for aggregate formation
(Fig. 1-3). The fact that some platelet adhesion is observed in the absence of GPVI
suggests that integrins can be activated to some degree through alternative pathways,
perhaps through GPIb/V/IX signaling or shear force-induced conformational change of
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integrins87,88. GPVI signaling also results in platelet degranulation, releasing ADP and
TXA2 that activate platelet G-protein coupled receptors in an autocrine and paracrine
fashion to augment platelet activation and promote aggregate growth (Fig. 1-3).
Furthermore, platelet activation through GPVI and positive-feedback pathways results in
flattening of the platelet shape, another requirement for efficient aggregate formation.
In vivo, platelet responses to collagen operate in conjunction with thrombin
generation by the coagulation cascade and contributions from endothelial cells, becoming
an increasingly complex process (Fig 1-1). Chapter 2 will address how GPVI signaling
has been adapted to efficiently transition the platelet from the rolling phase to the firmly
adherent phase. Chapter 3 will consider whether this model of collagen-induced
activation under hemodynamic flow holds true for avian species that have thrombocytes
instead of platelets.

Conclusions and outstanding questions
Platelet-mediated thrombus formation following atherosclerotic plaque rupture is the
leading cause of cardiovascular death. Studies aimed at understanding this
pathophysiology should focus on platelet activation and aggregation under conditions of
hemodynamic flow. Collagen is a primary activator of platelets and the Ig-domain
superfamily receptor GPVI is a platelet-specific receptor responsible for activation in
response to collagen and platelet-mediated thrombosis. While much progress has been
made in describing the function of GPVI, many questions remain. Those that will be
addressed in this dissertation include:
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How does GPVI, an immune-type receptor, function effectively to activate platelets under
hemodynamic flow conditions?
GPVI signal transduction utilizes a signal transduction pathway analogous to that of
immune receptors found on T-cells and B-cells. Receptor ligation induces clustering that
results in phosphorylation of ITAM-containing adaptor molecules—FcR! in the case of
GPVI—initiating a Syk, Slp-76, and PLC!2-dependent signaling cascade. A major
difference between immune cells and platelets is that signaling in immune cells is
designed to take place over the course of hours, through immune synapse formation and
results in gene transcriptional regulation. GPVI must activate the platelet extremely
rapidly to coordinate collagen-induced activation under conditions of hemodynamic flow.
Whether and how GPVI has adapted this immune receptor signaling pathway to better
suit the unique context of platelet physiology will be examined in Chapter 2.

Is collagen-induced platelet activation a conserved element of cellular hemostasis?
The ability of platelets to be activated by collagen is a fundamental aspect of platelet
biology, and collagen-induced activation is mediated through GPVI. Unlike other
platelet-specific receptors that are extremely well conserved, GPVI is unique to non-egglaying mammals. As an abundant and universal component of the subendothelial ECM in
all species, collagen is well suited to serve as a hemostatic activator, yet the presence of
GPVI appears to be a more recent product of evolution. In the nucleated thrombocyte, a
potential evolutionary precursor to the platelet, the ability to respond to collagen has not
been thoroughly examined and will be discussed in Chapter 3.

15

Is occlusive thrombus formation universal to cellular hemostasis?
Upon contact with collagen under hemodynamic flow, platelets form thrombi, and this
process can lead to vessel occlusion. The ability of platelets to mediate this response may
be advantageous to mammals as a response to traumatic injury, in order to prevent
catastrophic hemorrhage. Unfortunately, this platelet response contributes to pathologic
thrombosis in humans and is a major contributor to morbidity and mortality from
cardiovascular disease. Nucleated thrombocytes in avian species, which are larger and
less numerous than platelets in mammalian species, may respond differently under
hemodynamic flow conditions. The ability of thrombocytes to form 3-dimensional
aggregates under arterial flow conditions is unknown and will be examined in Chapter 3.
Determining whether avian thrombocytes are capable of this function will be informative
in understanding whether occlusive thrombus formation in response to vessel injury is a
conserved element of hemostasis in other warm-blooded organisms with a high-pressure
vascular system. Studying this phenomenon in avian species will provide insight into the
pathological mechanisms of mammalian platelet thrombosis that lead to human disease.
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Figure 1-1. A model for coagulation system and platelet activation following
vascular injury in flowing blood.
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Figure 1-1. A model for coagulation system and platelet activation following
vascular injury in flowing blood. Flowing blood generates shear forces that promote
platelet translocation along exposed collagen through GPIb/V/IX (GPIb) interaction with
Von Willebrand Factor (vWF). Collagen stimulates platelet activation through the GPVI
receptor (GPVI). Endothelial injury results in exposure of tissue factor (TF), which
activates coagulation factor VII (VII to VIIa-TF) and leads to factor IX activation.
Independently, exposed collagen supports factor XII (XII) autoactivation to enzymatic
factor XIIa (XIIa). XIIa initiates thrombin generation through a series of proteolytic
reactions involving activation of factor XI (XI to XIa), which activates factor IX (IX to
IXa). Factor IXa and activated factor VIII (VIIIa) activate factor X (X to Xa), which
along with activated factor V (Va) activates pro-thrombin (II) to thrombin. Thrombin
then stimulates platelets by activating its receptors, protease activated receptor 1 (PAR1)
and 4 (PAR4). PAR activation and GPVI signaling jointly contribute to platelet
activation, which results in activation of integrins (#2$1) to mediate firm adhesion to
collagen and exposure of procoagulant phophatidylserine (PS) on the platelet surface that
promotes coagulation factor assembly. These events converge to create a platelet
thrombus, which amplifies into a fibrin clot and leads to arterial vessel occlusion.
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Figure 1-2. GPVI signal transduction.
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Figure 1-2. GPVI signal transduction. Collagen binding GPVI induces receptor
clustering that allows SFKs Lyn and Fyn to phosphorylate tyrosine residues located on
the ITAM domain of the GPVI-bound FcR! chain. FcR! phosphorylation results in
recruitment of Syk kinase via its tandem SH2 domains. Syk phosphorylates LAT and
Slp-76 to assemble a signaling complex that includes the adaptor Gads bound to Slp-76.
Assembly of this complex facilitates activation of PLC!2, which binds LAT via its SH2
domain. Throughout this process, SFKs are active in phosphorylating signaling complex
components. PLC!2 cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to generate
inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), which mobilize Ca2+ and
activate PKC, respectively.
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Figure 1-3. The role of GPVI in platelet responses to collagen under flow.

Figure 1-3. The role of GPVI in platelet responses to collagen under flow.
A model for platelet responses to collagen during hemodynamic flow in the absence of
thrombin. Platelet rolling along the vessel edge is mediated by platelet GPIb/V/IX
interaction with collagen-bound vWF. Platelet rolling allows for GPVI to interact with
collagen and transduce signals that activate the platelet. “?” refers to additional activators
that can stimulate platelets in the absence of GPVI. Platelet activation induces three
essential processes: (1) shape change, which flattens the platelet profile, allowing for
more efficient contact with the collagen surface; (2) degranulation, which releases soluble
activators ADP and TXA2 that increase platelet activation; and (3) activation of highaffinity integrins #2$1 and #2b$3, which mediate firm adhesion to collagen and platelet
aggregation via fibrinogen binding, respectively.
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Chapter 2—Molecular priming of Lyn by GPVI enables an immune receptor to
adopt a hemostatic role

The data in Chapter 2 have been published in Proceedings of the National Academy of
Sciences of the United States of America152.

Summary
Circulating platelets use the immune receptor homolog glycoprotein VI (GPVI) to
respond to collagen exposed at sites of vessel injury. In contrast to immune cell
responses, platelet activation must take place within seconds to successfully form thrombi
in flowing blood. In this chapter, we show that the GPVI receptor utilizes a unique
intracellular proline-rich domain (PRD) to accelerate platelet activation, a requirement
for efficient platelet adhesion to collagen under flow. The GPVI PRD specifically binds
the Src-family kinase Lyn and directly activates it, presumably through SH3
displacement. In resting platelets, Lyn is constitutively bound to GPVI in an activated
state, and platelets lacking Lyn exhibit defective collagen adhesion like that of platelets
with GPVI receptors lacking the PRD. These findings define a molecular priming
mechanism that enables an immune-type receptor to adopt a hemostatic function. These
studies also demonstrate that active kinases can constitutively associate with immunetype receptors without initiating signal transduction before receptor ligation.
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Introduction
Platelets circulate in a quiescent state but are rapidly activated at sites of vessel injury, a
response essential for hemostasis in a high-pressure vascular system. Platelet activation
requires the generation of rapid and coordinated intracellular signals that culminate in
cell-matrix and cell-cell adhesion and thrombus formation within seconds10,85. Collagen,
the most abundant and thrombogenic subendothelial matrix protein exposed by vessel
injury, provides both a primary activating stimulus and an adhesive surface for the
initiation of platelet thrombi in the arterial system. Molecular and genetic studies have
established that collagen-induced platelet activation is triggered by the platelet-specific
surface receptor glycoprotein (GP)VI. GPVI is a low affinity collagen receptor and is not
capable of mediating direct adhesion to collagen under flow, but is required to signal in
response to collagen in order to mediate activation of the high-affinity integrin #2$1,
which mediates firm adhesion to collagen. The molecular mechanisms by which
circulating platelets respond to collagen are of intense interest because of collagen’s
primary role in arterial thrombosis.
GPVI is an immunoglobulin (Ig)-like domain-containing receptor that is
structurally and functionally homologous to immune receptors but is expressed
exclusively on platelets and megakaryocytes18,20. Extensive pharmacologic and genetic
studies have demonstrated that GPVI signaling in response to collagen is highly
analogous to that of the related multi-subunit T-cell receptor and the IgE and IgA
receptors46. GPVI ligands such as collagen or the snake venom toxin convulxin induce
receptor clustering that facilitates the phosphorylation of the tandem tyrosines found in
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the immunotyrosine activating motif (ITAM) of the non-covalently associated FcR!
chain adaptor by Src-family tyrosine kinases (SFKs), specifically Lyn and Fyn. ITAM
phosphorylation stimulates the recruitment and activation of the intracellular tyrosine
kinase Syk and assembly of an immune signaling complex (see Chapter 1). This
pathway, like the established G protein-coupled signaling pathways that mediate platelet
activation by thrombin and ADP, results in the elevation of intracellular calcium levels
and platelet activation responses, including granule release and integrin conformational
changes. In contrast to immune receptors that form stable immune synapses and transmit
signals which generate cellular responses over several hours, platelet activation by GPVI
takes place within seconds, allowing circulating platelets to firmly adhere to exposed
collagen36,89. Whether and how platelets have adapted the immune receptor homologue
GPVI to meet the accelerated temporal requirements inherent in hemostasis is unknown.
The signaling machinery of GPVI and other immune-type receptors is encoded by
their short transmembrane and intracellular domains. GPVI, like homologous immune
receptors, contains a conserved transmembrane arginine that is required for its association
with the FcR! chain, the essential signal transducing component of the receptor
complex21,90-92,93. However, a feature of GPVI that is unique among FcR!-coupled
receptors is a conserved intracellular class I (R/K)xxPxxP proline-rich domain (PRD) of
the amino acid sequence K/RPLPPLP that constitutes a core binding motif for SH3
domains such as those found on SFKs94 (Fig. 2-1A). Biochemical studies in cell lines
have demonstrated that the GPVI PRD mediates binding to the SFKs Lyn and Fyn95,96.
These studies have demonstrated variable degrees of reduced signaling by GPVI
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receptors lacking this motif59,95. Suzuki-Inoue et al. demonstrated reduced
phosphorylation of the FcR! chain following stimulation of GPVI lacking the PRD in
COS-7 cells transfected with GPVI constructs and FcR! chain95. They also demonstrated
an ablation of calcium mobilization in Jurkat T cells transfected with PRD-deleted GPVI,
which associates with the ITAM-containing %-chains in this cell95. Jurkat T cells do not
express Lyn, however. In contrast, Bori-Sanz et al. demonstrated a kinetic delay and
reduced signaling strength of a GPVI truncation mutant that removed the PRD and distal
C-terminal residues in rat basophilic leukemia (RBL)-2H3 cells that endogenously
express FcR! chain and Lyn59. The ability of cell line systems to accurately reproduce
platelet biology is severely limited and cannot be used for studies under hemodynamic
conditions. The role of the GPVI PRD in platelets and hemostasis has not been defined.
To study the function of the GPVI PRD, we generated mice with platelets that
expressed wild-type GPVI or GPVI lacking the PRD. Our studies reveal that the PRD
does not alter the strength of sustained GPVI signaling but instead accelerates platelet
activation kinetics, a feature required for the efficient adhesion of platelets to collagen
under flow conditions. Molecular studies to explain the basis for signal acceleration by
the GPVI PRD reveal that this domain specifically binds the SH3 domain of Lyn. We
find that GPVI PRD binding directly activates Lyn and that GPVI-bound Lyn in resting
platelets is in an active state prior to receptor ligation. These studies provide insight into
the molecular mechanism by which platelets have adapted the immune receptor signaling
pathway to function under the temporal constraints of the hemostatic system.
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Results
GPVI receptors lacking the intracellular PRD are expressed on mouse platelets
through retroviral transduction of hematopoietic progenitors.
The proximity of the genes encoding GPVI and the homologous human Fc#RI and
paralogous murine PIRa in the genome and their coupling to the FcR! transmembrane
adaptor support a common evolutionary origin for these Ig-like domain-containing
receptors19. However, a feature of GPVI that is unique among these FcR!-coupled
receptors is a conserved intracellular class I (R/K)xxPxxP PRD of the amino acid
sequence K/RPLPPLP. This region is a binding motif for SH3 domains such as those of
Lyn and Fyn, which phosphorylate the FcR! ITAM (Fig. 2-1A)47,95,97,98. The fact that
this proline-rich sequence is restricted to the GPVI receptor suggests that it confers a
platelet-specific signaling function.
To examine the role of the GPVI PRD in platelet signaling, we used retroviral
vectors to express wild-type human GPVI (WT GPVI) and a mutant lacking the PRD (PD
GPVI) in GPVI-deficient hematopoietic progenitors that were subsequently transferred to
irradiated host mice. The sequence of the cytoplasmic tail of human PD GPVI lacked 7
amino acid residues unique to the PRD and was identical to that shown by Suzuki-Inoue
et al. to no longer bind SFK SH3 domains (Fig. 2-1B)95. Fetal liver cells from GPVIdeficient embryos were infected with retrovirus driving the expression of GFP only, or
GFP with either WT GPVI or PD GPVI, and these cells were used to reconstitute lethally
irradiated wild-type host animals as previously described99. In chimeric animals
reconstituted with vectors that encoded WT or PD GPVI, GFP+ platelets co-expressed
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surface GPVI (Fig. 2-1C). As expected, these chimeric animals also contained a
population of GFP-/GPVI- platelets derived from GPVI-deficient donor cells that were
not successfully transduced with retrovirus (Fig. 2-1C). The level of surface GPVI
expression was constant and did not vary with the level of GFP expression (Fig. 2-1C),
most likely because surface expression of GPVI receptors requires, and is limited by, the
expression of endogenous FcR! co-receptors100. The levels of GPVI expression were
similar for WT GPVI and PD GPVI, indicating that both receptors are stably expressed
on the platelet surface, and these levels were comparable to those found on human
platelets (Fig. 2-1C and D).

Loss of the GPVI PRD does not alter sustained GPVI signaling in platelets.
Previous studies of GPVI signaling using cell lines have reported that GPVI receptors
lacking the PRD signal more weakly than wild-type receptors, with virtually no signaling
detected in the Jurkat T cell line and reduced signaling detected in the rat basophilic
leukemia (RBL)-2H3 mast cell line59,92,95. To test the role of the GPVI PRD in platelets,
we exposed platelets from reconstituted animals to varying concentrations of the GPVI
agonist convulxin for 10 min and measured platelet activation by the surface expression
of P-selectin that occurs following intracellular granule release. No significant difference
in platelet activation by convulxin was detected between platelets expressing WT GPVI
and PD GPVI receptors under these conditions (Fig. 2-2A and B). The ability of PD
GPVI platelets to spread and form lamellipodia on type-I collagen was not altered
compared to that of WT GPVI platelets, whereas vector control, GPVI-deficient platelets
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did not adhere well to collagen and did not spread on collagen (Fig. 2-2C and D).
Together, these results indicate that the GPVI PRD is not required for sustained signaling
in response to convulxin or collagen.

The GPVI PRD is required for rapid platelet activation by GPVI.
The GPVI PRD has been shown to bind the SFKs Lyn and Fyn, a finding which
suggested that this domain might accelerate the initiation of GPVI signaling by
facilitating the recruitment of Lyn and Fyn to the FcR! chain95,96. To test the importance
of the PRD in accelerating GPVI-mediated platelet activation, platelets were stimulated
with convulxin, and the degree of platelet activation at varying time points was analyzed.
Platelet activation was determined by the binding of the integrin #2b$3 ligand fibrinogen
or by the activation state-specific anti-#2b antibody JON-A. Consistent with the findings
illustrated in Figure 2-2B, at 45 s the degree of activation was identical for WT GPVI and
PD GPVI platelets (Fig 2-3A and B). At time points of up to 30 s following convulxin
stimulation, however, platelet activation was significantly impaired in platelets
expressing PD GPVI receptors compared with those expressing WT GPVI receptors (Fig.
2-3A and B). A delay in activation of PD GPVI platelets was also observed in response
to stimulation with collagen-related peptide (CRP), a synthetic collagen peptide specific
for GPVI that activates platelets more slowly than convulxin28, whereas sustained
signaling at timepoints of 90 and 180 sec was identical (Fig. 2-3C).
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P-selectin expression is an appropriate readout for measuring sustained GPVIinduced activation, whereas fibrinogen binding is preferable for measuring GPVI
signaling kinetics.
We have used P-selectin expression to compare platelet responses at 10 min, but we used
fibrinogen binding for kinetic analysis of platelet activation at shorter time intervals. The
rationale for this approach is that P-selectin expression is slow compared to integrin
activation/fibrinogen binding and does not provide as sensitive and accurate a means of
kinetic analysis. There is not a statistically significant increase in P-selectin expression
before 45 sec following convulxin stimulation (Fig. 2-4A). In contrast, fibrinogen
binding is detectable much earlier, i.e. by 10 sec, and there is a statistically significant
change between all early time points measured (Fig. 2-4B). Conversely, we have found
that the degree of fibrinogen binding can vary following a long stimulation, perhaps due
to late signaling that downregulates integrin affinity, while P-selectin expression reaches
a stable dose-dependent plateau and is therefore a good readout of total platelet
activation.

Loss of the PRD delays proximal GPVI signal transduction in RBL-2H3 cells.
The first step in signal transduction by the GPVI receptor is the phosphorylation of FcR!
intracellular tyrosines by SFKs, an event required for the binding and activation of the
downstream kinase Syk46. Retroviral complementation of GPVI-deficient bone marrow
yields a limited number of animals that are chimeric, and these reconstituted mice often
have a low percentage of platelets that express GPVI receptors. Therefore, we could not
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biochemically test the mechanism of delayed PD GPVI signaling in platelets. To
biochemically characterize PD GPVI signaling kinetics, we used lentiviral vectors to
stably express equivalent levels of WT GPVI and PD GPVI receptors in RBL-2H3 cells
(Fig. 2-5A). The RBL-2H3 mast cell line expresses endogenous FcR! chain and has been
used by our lab and others to study GPVI signaling59,92. Following stimulation with
convulxin, RBL-2H3 cells expressing PD GPVI exhibited delayed phosphorylation of
Syk, the kinase activated following FcR! ITAM phosphorylation, relative to that of WT
GPVI-expressing cells (Fig. 2-5B). However, total Syk phosphorylation at later time
points was unchanged (Fig. 2-5B). We attempted to measure the kinetics of FcR! chain
phosphorylation, the primary event in GPVI signaling, in WT- and PD-GPVI-expressing
RBL cells. However we were unable to detect FcR! phosphorylation in this cell line
system for technical reasons (data not shown). Lastly, elevation of intracellular Ca2+
was slower following GPVI stimulation in PD-GPVI expressing cells compared to that in
WT GPVI-expressing cells (Fig. 2-5C).

The GPVI PRD is required for efficient platelet adhesion to collagen under flow.
The physiologic role of the GPVI receptor is to activate circulating platelets that come
into contact with collagen at sites of vessel injury in vivo. Under experimental conditions
of blood flow over a collagen-coated surface, GPVI signaling is essential for the
transition from platelet rolling, mediated by the GPIb-von Willebrand Factor interaction,
to firm adhesion, mediated by activated #2$1 integrin-collagen interaction (see Chapter
1)10,36,40,85. To determine the role of the GPVI PRD during GPVI-collagen signaling
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under flow conditions, whole blood from reconstituted animals was flowed over a type-I
collagen patch in a microfluidic chamber, and platelet rolling and adhesion were analyzed
in real time. Since each reconstituted mouse is a chimeric animal containing different
percentages of GFP+/GPVI+ and GFP-/GPVI- platelets, the overall amount of platelet
accumulation was not representative of how efficiently individual platelets activated
transition from the rolling phase to firm adhesion. Therefore, the amount of platelet
accumulation could not be used to compare the function of WT GPVI and PD GPVI
receptors.
To overcome this limitation and analyze platelet adhesion in a cell-autonomous
fashion, each flow experiment was analyzed frame-by-frame, and all rolling platelets
were tracked to determine if and when they firmly adhered to the collagen surface (Fig.
2-6). An “adhesive efficiency” for each experiment was determined by a / (a + r), where
a equals the number of platelets that permanently adhered and r equals the number of
platelets that rolled along collagen but did not adhere. The difference in adhesive
efficiency between WT GPVI-expressing platelets and vector control, GPVI-deficient
platelets was profound and consistent with previous observations that GPVI-deficient
platelets are unable to adhere to collagen under flow conditions (Fig. 2-7A)36,40,70. A
majority of WT GPVI platelets that rolled along the collagen surface successfully
adhered, with an adhesive efficiency of 0.65 ± 0.11, whereas only a small number of
vector control GPVI-deficient platelets were able to transition from rolling to firm
adhesion, with an efficiency of 0.09 ± 0.04 (Fig. 2-7A). PD GPVI-expressing platelets
exhibited a markedly reduced adhesive efficiency of 0.31 ± 0.15, demonstrating that,
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compared to WT GPVI, approximately half as many PD GPVI platelets were able to
transition from the rolling phase to the firmly adherent phase (Fig. 2-7A).
A second measure of how efficiently platelets adhere to collagen is the time
required for each adherent platelet to transition from a rolling state to one of firm
adhesion, i.e. the time each adherent platelet spends in the rolling phase. Of the firmly
adherent platelets, WT GPVI platelets spent a shorter time in the rolling phase compared
to PD GPVI platelets (mean rolling time 711 ± 525 ms for WT GPVI versus 972 ± 674
ms for PD GPVI; P < 0.0005) (Fig. 2-7B and C), a finding consistent with the slower
kinetics of PD GPVI signaling which results in a longer time to activate platelet integrins
and mediate firm adhesion to collagen. These observations demonstrate that the GPVI
PRD is required for efficient platelet adhesion to collagen under flow, the ex vivo
response that most closely models the physiologic role of GPVI signaling in platelets in
vivo.

The GPVI PRD preferentially binds the SH3 domains of Lyn and Hck.
To identify all the SH3 domain-containing proteins that might bind the GPVI PRD, we
expressed WT GPVI and PD GPVI cytoplasmic tails as recombinant glutathione Stransferase (GST)-fusion proteins in E. coli (Fig. 2-8A). Incubation of these proteins
with platelet lysate followed by GST pulldowns demonstrated the ability of the GPVI
intracellular tail to bind Lyn and Fyn in a PRD-dependent manner (Fig. 2-8B). Next, we
used these recombinant proteins to screen a human SH3 proteome phage-display library
in order to identify the preferred SH3 domain binding partners for a number of proteins
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containing PRDs101. The WT GPVI fusion protein served as an excellent SH3 domain
target in this assay, binding approximately 1000-fold more SH3 domain-expressing
phage than did the PD GPVI fusion protein or GST alone (Fig. 2-8C). The identity of the
SH3 domains bound by GST-WT GPVI proteins was determined by sequencing the
inserts of the selected phage clones after a single round of affinity selection. Of 48 SH3
domains bound by GST-WT GPVI proteins, 40 encoded the SH3 domains of SFKs
(Table 2-I). Of 48 clones sequenced in 3 independent experiments, 40 encoded the SH3
domains of SFKs (Table 2-I). Remarkably, 35/40 encoded the SH3 domain of either Lyn
(16/40) or Hck (19/40) (Table 2-I). These results suggest that the SH3 domains of the
SFKs Lyn and Hck are specific binding partners of the GPVI PRD.
To test the results of the SH3 domain phage display screen, we determined which
of the putative partner proteins could be co-immunoprecipitated with endogenous GPVI
receptors in human platelets. Lyn co-immunoprecipitated with GPVI both under resting
conditions and following receptor stimulation with convulxin (Fig. 2-8D). In contrast,
Fyn was observed to associate with GPVI receptors following receptor stimulation but to
have little or no association with GPVI in the resting platelet (Fig. 2-8D). The Fyn SH3
domain was identified in the phage display screen, although as a rare binding partner
compared to Lyn or Hck (Table 2-I). As previously reported, Src did not coimmunoprecipitate with GPVI (Fig. 2-8D). Burton’s tyrosine kinase (Btk), whose SH3
domain was also identified by phage display as a less frequent GPVI tail binding protein,
did not associate with GPVI in platelets (Fig. 2-8D). Consistent with previous studies96,
we could not detect Hck expression in platelets (data not shown), suggesting that Hck is
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not a physiologically relevant GPVI binding partner. These findings identify Lyn as a
constitutive GPVI PRD binding partner in platelets.

GPVI PRD binding directly activates the Lyn and Hck kinases.
Constitutive recruitment of Lyn to GPVI via an SH3-domain/PRD interaction could
accelerate GPVI signaling merely by placing the kinase in close proximity to its
substrate, the FcR! ITAM. Alternatively, since SFKs can be activated via SH3-domain
displacement102, GPVI PRD-Lyn SH3 domain binding could directly regulate the kinase
activity of Lyn. Hck and Lyn are efficiently activated through SH3 binding by the HIV-1
protein, Nef102,103, and Hck and Lyn have been identified as the preferred binding
partners for the Nef SH3 domain using the same SH3 phage display screen as that
described above101. We therefore reasoned that the GPVI PRD might activate Hck and
Lyn through a mechanism similar to that of Nef.
To determine if the GPVI PRD can directly activate Hck and Lyn, we used an in
vitro kinase assay that has previously demonstrated direct Nef activation of these kinases
103

. Recombinant Hck, Lyn, and c-Src were expressed in insect cells with a C-terminal

modification that promotes autophosphorylation and confers an inactive kinase state103.
Purified kinase activity was then assayed in vitro with a peptide substrate, either alone or
in the presence of increasing concentrations of purified recombinant GST-WT GPVI,
GST-PD GPVI, or Nef protein. WT GPVI fusion protein activated Hck to a level
comparable to that of Nef at similar molar ratios (Fig. 2-9A). WT GPVI also induced
strong activation of Lyn, even at low GPVI:Lyn molar ratios, to a significantly greater
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extent than did Nef under the same conditions (Fig. 2-9B). PD GPVI fusion proteins
were unable to activate Hck or Lyn even at high molar excess, demonstrating the
requirement for the GPVI PRD to mediate kinase activation (Fig. 2-9A and B).
Consistent with the binding studies described above and with previous findings103, neither
WT GPVI nor Nef were capable of inducing c-Src activation in vitro (Fig. 2-9C). These
observations demonstrate that GPVI functions as a direct activator of Hck and Lyn kinase
activity, presumably via displacement of the intramolecular negative regulatory
SH3/linker interaction within these kinases by the GPVI PRD.

GPVI-bound Lyn is held in the active state in resting platelets.
To determine if GPVI-bound Lyn is found in an activated state in vivo, we
immunoprecipitated GPVI from human platelets under resting and stimulated conditions
and used phospho-specific antibodies to assess the kinase activation state. The SFK that
co-immunoprecipitated with GPVI under both resting and stimulated conditions was
phosphorylated at the activation loop, indicating that it was in the active state (Fig. 2-10).
More strikingly, none of the GPVI-bound Lyn was found to be phosphorylated on its
negative regulatory tail, despite a large amount of cellular Lyn that was found in this
inactive state (Fig. 2-10). These findings indicate that GPVI-associated Lyn is
exclusively in the active state even in resting platelets. The activation-loop
phosphotyrosine antibody used in these experiments recognizes all SFKs, but our studies
identified Lyn as the only SFK that associates with GPVI in resting platelets (Fig 2-8D).
In these assays the antibody reproducibly detected a doublet at 53 kD and 56 kD that is
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characteristic of Lyn (Fig. 2-10). To ensure that the detection of activated Lyn associated
with GPVI in resting platelets was not due to low-level platelet activation during cell
harvest, we assessed the phosphorylation state of the FcR! ITAM tyrosines. Robust FcR!
tyrosine phosphorylation was observed following 15 s of convulxin stimulation, but none
was observed in resting platelets (Fig. 2-10), although small amounts of basal FcR!
phosphorylation have been reported previously104. These findings demonstrate that the
Lyn associated with GPVI receptors in resting platelets is held in the active state but that
the FcR! ITAM is not phosphorylated in the absence of receptor ligand.

Lyn-deficient platelets exhibit the delayed GPVI receptor signaling and defective
adhesion to collagen under flow characteristic of PD GPVI platelets.
The studies described above suggest that the rapid early signal transduction conferred by
the GPVI PRD is dependent upon association with active Lyn. To test the dependence of
this mechanism on Lyn, we examined GPVI signaling and collagen adhesion under flow
in mouse platelets lacking Lyn or Fyn. As observed for PD GPVI platelets (Fig. 2-2), the
dose response of Lyn-deficient platelets stimulated with convulxin for 10 min was similar
to that of wild-type platelets (Fig. 2-11A), although at the lowest dose of convulxin
stimulation a gain of function was observed in Lyn-deficient platelets consistent with
previous findings47. However, when platelet activation responses were examined at short
time points following GPVI receptor stimulation, a delay in the activation of Lyndeficient platelets similar to that of PD GPVI platelets was observed (Fig. 2-11B). In
contrast, Fyn-deficient platelets did not demonstrate a significant delay in GPVI-induced
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platelet activation at short time points (Fig. 2-11C). Fyn-deficient platelets, however,
exhibited a defect in activation following convulxin stimulation for 10 min, as previously
reported (Fig. 2-11D)47. Like PD GPVI platelets, Lyn-deficient, but not Fyn-deficient,
platelets exhibited a significant defect in adhesion to collagen under flow (Fig. 2-12A and
B). These studies reveal that rapid GPVI signals require both the GPVI PRD and Lyn
kinase. Similar to loss of the GPVI PRD, loss of Lyn confers delayed GPVI receptor
signaling and defective adhesion to collagen under flow.
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Discussion
Immune-type receptors are expressed by non-immune cells where they have adopted new
functions, but the molecular adaptations that have fostered such novel roles remain
unknown. In the present study we identify the binding and direct activation of Lyn by the
PRD of the GPVI receptor as a molecular mechanism by which platelets accelerate
immune receptor signaling to adapt it to hemostasis, a biological response that must take
place within seconds. Previous studies have demonstrated that the GPVI PRD binds
SFKs and contributes to GPVI signaling in cell lines95,96, but the molecular consequences
of GPVI PRD interaction with SFKs and the functional role of this interaction in platelet
responses was unknown. Our results demonstrate that the PRD is not essential for GPVI
signaling, but instead primes the receptor for rapid platelet activation required for
efficient adhesion to collagen in the setting of blood flow by binding and directly
activating Lyn. Additionally, these findings identify a novel molecular mechanism by
which an immune receptor has become a hemostatic receptor, and they provide insight
into the basic mechanisms of immune receptor signal transduction.
The activation of circulating platelets by exposed vessel wall collagen must take
place within seconds for effective hemostasis, and GPVI is essential in this process
10,36,40,70,85

. GPVI is an immune-type receptor that signals through a pathway

characterized by sustained and progressive signaling responses that do not typically result
in extremely rapid cellular responses89,105. A large number of molecular and genetic
studies have demonstrated that GPVI signaling in platelets is similar to that of related
receptors in immune cells16,22,44-50. While these studies have confirmed that GPVI is
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functionally a bona fide member of the immune receptor family, they have not addressed
the way in which this signaling pathway has been adapted in platelets to serve a
hemostatic role. Our findings suggest that the GPVI PRD is therefore a specialized
region that accelerates immune-receptor signaling to function in a non-immune,
hemostatic role.
This study provides new biological insight into the molecular regulation of SFKs
through identification of an unexpected mechanism by which the GPVI PRD accelerates
immune receptor–induced cellular activation. The GPVI PRD selectively binds the SH3
domains of Lyn and Hck and directly activates these kinases in vitro. The ability of the
GPVI PRD to activate Lyn directly by binding to its SH3 domain provides a striking
example of how this mechanism, first described in studies of the HIV-1 Nef protein, has
an important role, not previously appreciated, in endogenous biological responses106,107.
Studies of Hck activation by Nef support a model in which binding of Nef to the SH3
domain of Hck displaces the SH3 domain from an intramolecular association with a
polyproline II helix in the SFK linker that holds the kinase in an inactive state108.
Although studies of Nef have demonstrated SH3 domain displacement to be a potent
mechanism of SFK activation that likely contributes to HIV virulence102,103, the extent
and purpose to which endogenous proteins activate SFKs by this mechanism is not clear.
Our studies suggest that GPVI activation of Lyn occurs through a Nef-type SH3
displacement mechanism, although structural studies comparing SFK activation by these
two proline-rich polypeptides are needed to determine whether or not they are
molecularly identical. Interestingly, our in vitro studies demonstrate that, like Nef, the
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GPVI PRD can activate forms of Lyn and Hck which are phosphorylated at their
negative-regulatory C-terminal tail tyrosines, suggesting that these two regulatory
mechanisms can function independently109,110. However, our analysis of GPVIassociated Lyn in platelets reveals that virtually none is C-terminally tyrosine
phosphorylated, suggesting that GPVI binding to the Lyn SH3 domain may also
positively regulate kinase activity by promoting dephosphorylation at this negative
regulatory site. Future studies addressing the molecular basis of Lyn activation by GPVI
may reveal whether and how these two molecular mechanisms of SFK regulation are
coordinated in vivo.
While both Lyn and Fyn are required for optimal GPVI signaling47, our studies
suggest Lyn, but not Fyn, drives the explosive GPVI signaling required for adhesion to
collagen under flow. The preference of the GPVI PRD for binding Lyn over Fyn and the
observation that Lyn, but not Fyn, binds GPVI receptors in resting platelets support a
division of labor in which PRD-bound Lyn drives initial GPVI-induced platelet activation
and Fyn participates in more sustained GPVI signaling. This model of SFK signaling
downstream of GPVI is supported by biochemical studies demonstrating a delay in FcR!,
Syk and PLC!2 phosphorylation following GPVI stimulation of Lyn-deficient
platelets111. Consistent with this model, PD GPVI receptors exhibit delayed Syk
phosphorylation and calcium signaling in RBL-2H3 cells.
A final question raised by these findings is whether GPVI-bound activated Lyn
affects other Lyn substrates in the platelet. There are roughly 1500 GPVI receptors
expressed on the platelet surface58, a number that is likely to be considerably lower than
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the total quantity of intracellular Lyn. We therefore speculate that GPVI-induced
activation of Lyn is unlikely to significantly affect the phosphorylation of other Lyn
substrates because of both physical sequestration of the activated kinase and the relatively
small effect on the activation state of total Lyn.
Our studies also provide unexpected insight into ITAM activation, a primary step
in all immune receptor signal transduction. An apparent paradox raised by our findings is
how the GPVI receptor can constitutively associate with activated Lyn kinase yet not
phosphorylate the ITAM of its co-receptor FcR! and activate the resting platelet. A
recent study of ITAM phosphorylation by the T cell receptor has revealed that the CD3&
ITAM is embedded in the lipid bi-layer of the cell membrane and sequestered from
activating SFKs in unstimulated cells112. Through a yet undefined mechanism, T cell
receptor ligation and clustering result in release of the ITAM from the membrane,
exposure to SFKs, and initiation of downstream receptor signaling112. These findings
suggest that a similar sequestration of the FcR! ITAM in the cell membrane may allow
activated Lyn to be held by GPVI in the immediate proximity of the FcR! subunit
without initiating signal transduction prior to receptor-ligand interaction (Fig. 2-13).
Future studies of GPVI-FcR! signaling in platelets, e.g., mutation of the acidic membrane
proximal residues in FcR! proposed to mediate lipid interaction and separation from the
GPVI receptor tail93,112, may be informative regarding both the basis of signal
acceleration by the GPVI PRD and ITAM signaling by immune receptors.
It is intriguing to consider the appearance of the GPVI PRD in the context of
platelet and immune receptor evolution. Adaptive immunity and ITAM signaling
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receptors emerged over 500 million years ago with jawed vertebrates113, while platelets
appeared more recently in mammals, 300 million years ago7. The GPVI receptor is
encoded by a gene in the leukocyte receptor complex (LRC), a region of the mammalian
genome that underwent rapid evolution between egg-laying mammals, such as the
platypus, and placental and marsupial mammals114,115. Consistent with its location within
the re-organized mammalian LRC, homology-based searches reveal clear GPVI orthologs
in the genome of placental and marsupial mammals but not in the platypus or avian
genomes. Thus the GPVI receptor appears to have evolved with other LRC immune
receptors after platelets had already appeared in mammals (see Chapter 3). Alignment of
the predicted opossum and human GPVI receptor amino acid sequences reveals the
presence of a highly conserved intracellular PRD that is present in all known GPVI
receptors (Fig. 2-1A). These observations suggest that acceleration of immune receptor
signaling by the PRD may have been instrumental in the evolution of GPVI as a platelet
collagen receptor.
The identification of a molecular mechanism by which an immune-type receptor
accelerates signal transduction to perform a hemostatic function in platelets may also
direct new therapeutic strategies to treat cardiovascular disease. Collagen activation of
platelets is a primary event in the formation of arterial thrombi that cause heart attack and
stroke. Agents that target the PRD of GPVI may selectively block rapid platelet collagen
responses without inhibiting overall hemostasis and non-hemostatic immune receptor
signaling.
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Materials and methods
Animals
GPVI-deficient and Lyn-deficient mice have been previously described54,116. Wild type
C57/BL6 mice were purchased from Charles River Laboratories (Wilmington, MA). All
of the mice used for study were maintained in the animal facility of the University of
Pennsylvania in accordance with National Institute of Health guidelines and approved
animal protocols.

Antibodies and reagents
Anti-human GPVI monoclonal antibodies HY101 and 6B12 were produced as previously
described 58 and were conjugated with Alexa Fluor-647 using the Monoclonal Antibody
Labeling Kit purchased from Molecular Probes (Eugene, OR). Convulxin, AYPGKF
peptide, and PE-conjugated anti-murine CD62P (P-selectin) antibody were purchased
from previously described sources117. Collagen-related peptide (CRP) was obtained from
Dr. Richard Farndale (Cambridge, UK). FITC-conjugated polyclonal anti-rabbit Ig was
purchased from BD PharMingen (Eugene, OR). JON/A, JAQ1, and Leo.H4 monoclonal
antibodies were purchased from Emfret Analytics (Eibelstadt, Germany). Type-I fibrillar
collagen (1 mg/mL) derived from equine tendon was purchased from Chronolog
(Havertown, PA). Purified acid-soluble fibrillar collagen (PureCol™) derived from
bovine hide (3 mg/mL) was purchased from Inamed (Freemont, CA). Rat anti-mouse
CD41 (integrin #2b) monoclonal antibody was purchased from BD Biosciences (San Jose,
CA). Alexa-Fluor 488 and 647 Monoclonal Antibody Labeling Kits, Alexa-Fluor 647-
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conjugated human fibrinogen, and Alexa-Fluor 594-conjugated phalloidin were
purchased from Invitrogen (Carlsbad, CA). Murine stem cell factor (MSCF), IL-3 and
IL-6 were purchased from PeproTech (Rocky Hill, NJ). Anti-GFP, anti-Lyn, anti-Fyn,
anti-Syk, and anti-Btk rabbit polyclonal antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-FcR! chain rabbit polyclonal antibody was
obtained from Abcam (Cambridge, MA). Anti-phosphotyrosine mouse monoclonal
antibody 4G10 was obtained from Millipore (Billerica, MA). Anti-phospho Src family
(Y416), anti-phospho Lyn (Y507), and anti-phospho Syk (Y525/526) rabbit polyclonal
antibodies, and anti-Src rabbit monoclonal antibodies were obtained from Cell Signaling
(Beverly, MA).

Retrovirus production
The cDNA of human GPVI was subcloned into the p-GEM-T Easy vector (Promega,
Madison, WI), and site-directed mutagenesis to remove the PRD was performed using the
Stratagene QuickChange site-directed mutagenesis kit (La Jolla, CA). The
oligonucleotide used for site-directed mutagenesis has been previously described95.
Wild-type and PRD deleted GPVI were subcloned into XhoI/HpaI sites of the murine
stem cell virus MigR1 vector with an IRES-GFP inserted prior to the polyadenylation
signal, as described previously99. Production and titering of retrovirus was performed as
previously described118. For RBL-2H3 cell infections, wild-type GPVI and GPVI
lacking the proline-rich domain were subcloned into XbaI/EcoRI sites the HFUW
lentiviral vector (kind gift from Dr. Eric Brown from Department of Cancer Biology,
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University of Pennsylvania School of Medicine). The lentiviral vectors were packaged
using HEK 293T cells.

Fetal liver reconstitution
Reconstitution of lethally irradiated animals with stem cells derived from fetal liver was
performed as previously described99. Briefly, fetal liver cells from gp6-/- embryos at E14E16 were harvested, and mononuclear cells were isolated using Lympholyte (Cedarlane
Labs, Burlington, NC) gradient and cultured overnight in IMDM (Invitrogen) with 10%
fetal bovine serum in the presence of 100 ng/mL MSCF, 20 ng/mL IL-3, and 10 ng/mL
IL-6. The cells were then spin-infected twice with gp6 retroviruses at a multiplicity of
infection equal to 5 virions per cell. A total of 1 x 106 cells (250 !L per mouse) were
retro-orbitally injected into 8-10-week-old C57/BL6 donor mice that received a lethal
dose of 900 cGy total body irradiation. All platelet studies were performed at least 6
weeks after transplantation.

GPVI antibody staining
For mice, a drop of blood was collected from the tail vein, whereas for humans a drop of
blood was obtained from a finger-stick from a healthy donor into 100 µL of Tyrode’s
buffer (137 mM NaCl, 1 mM MgCl2, 2.7 mM KCl, 3.3 mM NaH2PO4, 1 g/L BSA, 5.6
mM glucose, 20 mM HEPES, pH 7.4) containing 15 U/mL heparin. Diluted whole blood
was incubated with Alexa-Fluor 647-conjugated HY101 anti human GPVI antibody at 2
!l/mL for 30 min at room temperature, and samples were analyzed using flow cytometry.
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Murine blood collection
Mice were anesthetized with 16 !g/g body weight tribromoethanol, and 100 !L of whole
blood was collected by retro-orbital bleeding with a heparinized capillary tube. Plateletrich plasma (PRP) was obtained by diluting whole blood 1:2 in Tyrode’s buffer and
performing centrifugation at 100 g for 4 min.

Platelet spreading assay
Lab-Tek II chamber slides (Thermo Fischer Scientific, Rochester, NY) were coated with
type I fibrillar collagen at 30 µg/mL in 50 µM acetic acid for 16 h at 4 °C, washed 3
times with PBS, and blocked with BSA 1 mg/mL in PBS for 30 min at room temperature.
PRP was diluted to 2 x 107 platelets per mL in modified Tyrode’s buffer (137 mM NaCl,
20 mM HEPES, 2.7 mM KCL, 3.3 mM NaH2PO4, 5.6 mM glucose, 1 g/L BSA, pH 7.4)
containing 1 mM MgCl2, and 5 x106 platelets were incubated on the collagen-coated
chambers for 45 min at 37°C. Fixation, permeablizing, and staining were performed as
previously reported119. Following 3 washes in PBS, adherent platelets were fixed with
3% paraformaldehyde in PBS for 40 min, washed 3 times in PBS, and permeablilized
with 0.3% Triton X-100 in PBS with BSA 1 mg/mL for 2 h. After 3 washes in PBS,
platelets were incubated with anti-GFP rabbit polyclonal antibody (10 µL/mL) for 16 h at
4°C, washed 3 times in PBS, and incubated with FITC-conjugated polyclonal anti-rabbit
Ig (2 µL/mL) for 2 h at room temperature. Filamentous actin was stained with AlexaFluor 594-conjugated phalloidin (25 µL/mL) for 45 min at room temperature. Platelet
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spreading was imaged as previously described99, and only platelets with both GFP and
actin staining were visualized. Platelet surface area was measured in pixels using Image
J software (National Institutes of Health, Bethesda, MD) particle analysis. Particles of
sizes from 250 to 4050 pixels, which represented those well-separated platelets, were
measured.

Platelet stimulation assays
Platelet stimulation assays quantified by flow ctytometric analysis were perfomed as
previously described99. Platelet-rich plasma (PRP) was diluted to 2.5 x 107 platelets per
mL in modified Tyrode’s buffer, and 2.5 x 106 platelets were stimulated with varying
concentrations of convulxin for 10 min at 37°C in the presence of PE-conjugated antimurine P-selectin antibody (2 µL/mL, BD Biosciences) and 1 mM CaCl2 and MgCl2. In
time-course assays, 2.5 x 106 platelets were stimulated were stimulated with 10 nM
convulxin (Alexis) or 10 µg/mL CRP for the time indicated in the presence of AlexaFluor 647-conjugated fibrinogen, and the reaction was stopped by addition of 1%
paraformaldehyde for 5 min followed by washing. In time course assays using JON/A
antibody binding, platelets were stimulated with 10 nM convulxin for the time indicated
at room temperature, and the reaction was stopped by addition of 1% paraformaldehyde
for 5 min followed by washing. Platelets were then stained by addition of PE-conjugated
JON/A antibody (10 µL/mL) for 30 min at room temperature. Fibrinogen and antibody
binding were measured with a FACSort (BD Biosciences, San Jose, CA), and the data
were analyzed with FlowJo 6.3.1 software (Tree Star, Ashland, OR).
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Ca2+ mobilization assays
RBL-2H3 cells were labeled with Fura-2 AM (Molecular Probes, Eugene OR), and
calcium signaling was detected as previously described58. Briefly, RBL-2H3 cells
transfected with lentivirus driving expression of WT or PD GPVI or vector alone were
grown to confluence in a 10 cm culture dish and many cells had detached from the dish
surface. These non-adherent RBL-2H3 cells are perfectly viable. Floating and adherent
cells were isolated by successive aspiration, washed in RHB medium (RPMI 1640
[Invitrogen] containing 25 mM HEPES and 1 mg/mL BSA), and resuspended to a
concentration of 2 x 107 cells per mL. Fura-2 AM was added to the cell suspension at a
final concentration of 4 µg/mL and incubated at 37 °C in 5% CO2 for 30 min. Cells were
washed twice in RHB medium and resuspended in RHB medium at a concentration of 2 x
106 cells per mL. Aliquots of 1.4 mL of labeled cells were analyzed in a Fluorescence
Spectrometer under stirring conditions following addition of agonist.

Fabrication of microfluidic devices, collagen patterning, and whole blood flow assay
Fabrication of microfluidic devices and microfluidic collagen patterning was performed
as previously described 39. Channels were initially filled with 1 mg/mL BSA in HBS to
ensure that no bubbles were trapped in the channel. Whole blood from reconstituted
mice was collected retro-orbitally as described above. Blood was incubated with JAQ-1
antibody at 25 µg/mL for 10 min, to block any wild-type mouse GPVI on platelets
derived from host precursors that escaped bone marrow ablation, and with 5 µg/mL
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Leo.H4 monoclonal antibody, to prevent aggregate formation for ease of analysis. Whole
blood from lyn-/- or fyn-/- mice and wild-type controls was collected retro-orbitally in
heparinized capillary tubes, labeled with Alexa-Fluor 488-conjugated CD41 antibody,
and incubated with 5 µg/mL Leo.H4. A volume of 70 µL of whole blood was placed on
the inlet of the device and withdrawn by a syringe pump (Harvard Apparatus PHD 2000,
Holliston, MA) for up to 4 min at flow rates of 5 µL/min to achieve a full channel widthaveraged wall shear rate of ! chan = 1000 s-1.

Image capture and analysis
The adhesion of GFP+ platelets or fluorescently labeled platelets was monitored
continuously by epifluorescence microscopy. For blood from reconstituted animals,
images were captured continuously with a 60-200 ms exposure time depending on the
percentage of GFP+ platelets in each mouse at an interval of 100 ms using Slidebook
software (Intelligent Imaging Innovations). Every new rolling platelet that appeared was
tracked in subsequent frames to determine if it ultimately adhered firmly to the collagen
surface or if it continued to roll but did not adhere. All analyses were performed with the
observer blinded to the identity of the sample. All image stacks were analyzed frame-byframe in Slidebook. Any platelet that was captured by fluorescent imaging was presumed
to be rolling along the collagen surface, as non-rolling GFP+ platelets, leukocytes, and
red blood cells moved too fast to be visualized. Each frame was analyzed to determine if
a new platelet began to roll on the patterned collagen surface. Firmly adherent platelets
were defined as ones that did not change position for at least 30 frames. Platelets that
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came in contact with the wall of the flow chamber were not counted. Platelets that rolled
as a pre-formed clump or adhered to pre-existing platelet clumps and not to the collagen
surface directly were not counted. Each experiment was only analyzed as long as
individual platelet-collagen interactions could be distinguished. In determining the
number of frames each adherent platelet spent rolling, the last frame before the platelet
changed position for a final time was counted. Thus, a platelet that was permanently
adhered by the first frame in which it was observed was counted as rolling for zero
frames, and the rolling time consisted only of the interval before the frame in which the
platelet appeared. The adhesive efficiency for each image stack was determined by
calculating a / (a + r), where a equals the number of platelets that permanently adhere
and r equals the number of platelets that roll along collagen but do not adhere. The time
each adherent platelet spent in the rolling phase was calculated as (F)(Ex) + (F + 1)(Int),
where F equals the number of frames the platelet spent rolling, Ex equals the exposure
time per frame, and Int equals the interval time between captures, which was 100 ms for
all experiments.
Images were captured using a CCD camera (C9300-201 Hamamatsu,
Bridgewater, NJ) mounted on an inverted microscope (Nikon Eclipse TE2000-U,
Melville, NY) with a 300 W Xenon lamp (Perkin Elmer Optoelectronics, Freemont, CA)
through a Lambda DG-4 high-speed filter changer (Sutter Instruments, Novato, CA) used
at 470 nm Ex / 525 nm Em. For blood flow experiments from Lyn-/- or Fyn-/- mice or
wild-type controls, the collagen patch was defined using Image J software (National
Institutes of Health, Bethesda, MD). The average background of the upstream region was

50

calculated for each column and those values were subtracted from the reaction zone pixel
values to correct for background gradients across the width of the channel. Surface
coverage was calculated by dividing the area of pixels with a value greater than zero by
the area of the collagen patch.

Production of GST-fusion proteins and expression of recombinant SFKs and Nef
GST fusion proteins of the GPVI C-tail were prepared from cDNA encoding the WT or
PD GPVI sequence beginning from Glu269 to the terminal Ser residue using forward
primer 5’-TAGAATTCGAGGACTGGCACAGCCGGAGGAA-3’ and reverse primer
5’-TACTCGAGTCATGAACATAACCCGCGGCTGTG-3’. Fragments were subcloned
into EcoRI/XhoI sites of pGEX4T-1, and proteins were expressed in E. coli according to
manufacturer instructions, purified with glutathione agarose (Amersham Biosciences,
Piscataway, NJ). Human Hck, Lyn, and c-Src were expressed in Sf9 insect cells and
purified to homogeneity as previously described103. The C-terminal sequence of each
SFK was modified to Tyr-Glu-Glu-Ile-Pro, which promotes autophosphorylation of the
tail tyrosine and permits high yield purification of the downregulated form of each
kinase103. The SF2 allele of HIV-1 Nef was expressed in bacteria and purified as
previously described103.

Phage display
The phage-displayed SH3 domain library panning onto purified target proteins was
performed as previously described101. Briefly, 6-well tissue culture plates (Cellstar) were
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coated with 20 !g/mL bacterially expressed purified GST fusion proteins of the GPVI Ctail and the GPVI C-tail lacking the PD sequence or, in control experiments, GST protein
alone (1.5 mL per well) in 50 mM Na-carbonate buffer pH 9.6 overnight at 4ºC. The
subsequent steps were performed at room temperature. The plates were washed 3 times
with 2 mL of TBS-T buffer (Tris-buffered saline [TBS] supplemented with 0.05% Tween
20) and incubated with blocking solution (5% non-fat milk in TBS-T) for 2h, followed by
incubation with the mixture of human SH3 library-displaying phages (109-1010 pfu/well)
prepared in TBS-T and supplemented with 2.5% of non-fat milk for 2 h. Subsequently,
the phage mixture was removed and plates were washed 4 times with 2 mL of TBS-T.
The infection of TG1 bacteria by phages that remained bound to GPVI C-tail proteins or
GST alone was carried out by adding 1 mL of log-phased cells (OD600 = 0.5-0.6) to each
well followed by incubation at 37ºC for 1h. Subsequently, different dilutions of infected
TG1 (1:1, 1:10, 1:100, and 1:1000) were seeded onto ampicillin-containing LB plates.
The next day, the resultant colony numbers from WT GPVI C-tail and from PD GPVI Ctail were compared to the number of colonies obtained from the control (GST alone)
plate. WT GPVI C-tail-interacting SH3 domains were identified by performing a
sequencing reaction (sequencing primer 5’-CCTATTGCCTACGGCAGCC-3’) on the
SH3 domain-encoding phagemides that were isolated from individual bacterial colonies.

Immunoprecipitations from platelet or RBL-2H3 cell lysate
Blood was collected from 5 healthy donors into 30 or 60 mL syringes containing 5 or 10
mL of acid citrate dextrose. Platelets were isolated from platelet-rich plasma by
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centrifugation in the presence of 1 U/mL apyrase and 1 µM prostacyclin and washed
once in platelet wash buffer (10 mM HEPES, 1 mM EDTA, 150 mM NaCl, pH 6.0)
before resuspending in modified Tyrode’s buffer. 6 x 108 washed platelets were
stimulated with 10 nM convulxin or left unstimulated at 37º C with stirring, and reactions
were terminated with addition of 5x lysis buffer (1% NP-40, 50 mM Tris pH 7.4, 150
mM NaCl, 2 mM EDTA final concentration) with a 1:50 dilution of EDTA-free protease
inhibitor cocktail (Roche Diagnostics, Indianapolis, IN) and a 1:100 dilution of HaltTM
phosphatase inhibitor cocktail (Thermo Scientific, Rockford, IL). Transfected RBL-2H3
cells were incubated in RPMI at 37ºC for 30 min at a concentration of 1 x 107 cells per
mL. 6 x 106 RBL-2H3 cells were stimulated with 1 nM convulxin or left unstimulated at
37º C with stirring, and reactions were terminated with addition of an equal volume of
ice-cold 2x NP40/dodecyl maltoside lysis buffer (1.6% NP-40, 2% dodecyl maltoside, 20
mM Tris, pH 7.5, 300 mM NaCl, 4 mM EDTA, 2 mM dithiothreitol)105, with protease
and phosphatase inhibitors as described above. Samples were lysed for 1 h at 4ºC, and
insoluble material was pelleted by centrifugation at 15,000 g for 20 min. For GST-fusion
immunoprecipitation, lysate was incubated with glutathione-sepharose beads conjugated
with GPVI GST-fusion protein. For GPVI immunoprecipitation, lysate was incubated
with 5 µg/mL HY101 monoclonal antibody or 5 µg/mL mouse IgG for 2 h at 4ºC before
addition of protein-A sepharose and overnight incubation with rocking. Sepharose beads
were pelleted and washed 4 times for 5 min in 1x lysis buffer before addition of Laemmli
sample buffer with 2.5% $-mercaptoethanol and boiling for 10 min. Samples were run
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on 4-12% v/v gradient SDS-polyacrylamide using MOPS electrophoresis buffer,
transferred to PVDF membranes, blocked, and probed with antibody.

In vitro kinase assays
Production of recombinant HIV-1 Nef and tyrosine kinase assays were performed in 384well plates using the Z’-Lyte kinase assay system and the Tyr2 peptide substrate
(Invitrogen) as previously described103. Briefly, to assess the effect of GPVI compared to
Nef on SFK activity, Hck (20 ng), Lyn (50 ng), or c-Src (50 ng) was incubated at room
temperature for 5 min with increasing molar concentrations of GST-WT GPVI, GST–PD
GPVI, or Nef. Purified GST-fusion proteins were dialyzed to remove free glutathione
prior to use in in vitro kinase assays. ATP (100 !M final) and Tyr2 substrate (1 !M
final) were then added to the reaction, and samples were incubated for 1 h (45 min for
Hck). Development reagent, which contains a protease that digests non-phosphorylated
peptide, was then added, and samples were incubated for an additional 60 min before
termination of the reaction with stop reagent. Fluorescence was assayed, based on FRET
between coumarin and fluorescein in the phosphorylated (uncleaved) substrate peptide
only. Raw fluorescence values were corrected for background, based on a 0%
phosphorylation (no ATP) negative control, and reaction endpoints were calculated as
emission ratios of coumarin fluorescence divided by the fluorescein FRET signal. These
ratios were then normalized to the ratio obtained with a 100% phosphorylation control
peptide. Each condition was assayed in quadruplicate, and results are presented as the
mean ± SD.

54

Statistics
P values were calculated using an unpaired two-tailed Student’s t test assuming unequal
variance.

55

Figure 2-1. Expression of wild-type GPVI receptors and GPVI receptors lacking
the intracellular PRD in GPVI-deficient mouse platelets using retroviral vectors.
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Figure 2-1 (cont’d). Expression of wild-type GPVI receptors and GPVI receptors
lacking the intracellular PRD in GPVI-deficient mouse platelets using retroviral
vectors.

57

Figure 2-1. Expression of wild-type GPVI receptors and GPVI receptors lacking
the intracellular PRD in GPVI-deficient mouse platelets using retroviral vectors.
A. Alignment of the predicted transmembrane and intracellular amino acid sequences
from opossum (d), mouse (m), and human (h) genes encoding the GPVI receptor, the
homologous and paralogous human Fc alpha receptor (Fc#RI), and the mouse paired Iglike receptor (PIR)a. The amino acids shown in orange are involved in coupling of the
receptor to the transmembrane signaling adaptor FcR!. The amino acids shown in red
constitute a binding motif for SH3 domains. Note the lack of the GPVI PRD in
homologous immune receptors. B. The amino acid sequences of the cytoplasmic tails of
the wild-type human GPVI (WT GPVI) and mutant GPVI lacking the proline-rich region
of the cytoplasmic tail (PD GPVI) are shown. The sequence of the cytoplasmic tail of
human PD GPVI lacked 7 amino acid residues unique to the PRD and was identical to
that shown by Suzuki-Inoue et al. to no longer bind SFK SH3 domains95. C. Retroviral
co-expression of GPVI receptors and GFP in GPVI-deficient mouse platelets. Retroviral
vectors were used to co-express GFP only (vector), or GFP with either WT GPVI or PD
GPVI, in GPVI-deficient fetal liver cells that were subsequently used to reconstitute
lethally irradiated mice. Shown are GFP and surface GPVI expression in the platelets of
animals reconstituted with cells exposed to empty vector (vector), vector driving
expression of WT GPVI, vector driving expression of PD GPVI, and human platelets.
GFP+ platelets expressing surface WT GPVI and PD GPVI are shown in red boxes.
D. Expression levels of human GPVI on mouse platelets. Shown are histograms of
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surface GPVI in GFP-positive platelets from the indicated reconstituted mice compared
to GPVI on human platelets.
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Figure 2-2. Loss of the GPVI PRD does not alter sustained GPVI receptor signaling
in platelets.
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Figure 2-2. Loss of the GPVI PRD does not alter sustained GPVI receptor signaling
in platelets. A. Platelet activation mediated by WT and PD GPVI signaling. Platelets
from GPVI-deficient mice expressing WT GPVI or PD GPVI receptors were stimulated
with the indicated concentrations of convulxin for 10 min, and activation was measured
using flow cytometry to detect the expression of surface P-selectin in GFP+, GPVIexpressing platelets. AYP indicates exposure to the PAR4 agonist peptide AYPGKF.
B. Dose-response curve of platelet activation mediated by WT and PD GPVI signaling.
C. Platelet spreading on collagen mediated by WT or PD GPVI. Platelets from the
indicated mice were incubated for 45 min on immobilized type-I collagen, and spreading
was visualized by staining with Alexa-Fluor 594-conjugated phalloidin to detect cellular
actin. GFP expression was simultaneously measured to identify platelets derived from
vector-transduced precursors. D. Quantitation of platelet spreading driven by WT GPVI
or PD GPVI, depicted in panel C. The area occupied by adherent platelets was measured
using the Image J program. n = 100-300 individual platelets from 2-3 different animals
analyzed for WT or PD GPVI or vector control.
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Figure 2-3. The intracellular PRD is required for rapid platelet activation by GPVI
receptors.

62

Figure 2-3. The intracellular PRD is required for rapid platelet activation by GPVI
receptors. A. Time course of platelet fibrinogen binding by WT and PD GPVIexpressing platelets following convulxin stimulation. Platelets were stimulated with 10
nM convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times
indicated, fixed, and analyzed by flow cytometry. B. Time course of JON-A binding
following 10 nM convulxin stimulation. C. Time course of fibrinogen binding following
stimulation with 10 µg/mL CRP. In all experiments only GFP+, GPVI-expressing
platelets were analyzed. * = P <0.05, ** = P <0.01; error bars indicate mean ± SD; n =
3-6 experiments for each time point indicated, using 4 animals for WT or PD GPVI.
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Figure 2-4. Time course analysis of P-selectin expression and fibrinogen binding
following convulxin stimulation in wild-type platelets.
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Figure 2-4. Time course analysis of P-selectin expression and fibrinogen binding
following convulxin stimulation in wild-type platelets. A. Time course of P-selectin
expression following convulxin stimulation. Wild-type mouse platelets were stimulated
with 10 nM convulxin for times indicated in the presence of antibody against P-selectin,
and P-selectin expression was determined by flow cytometry. B. Time course of platelet
fibrinogen binding following convulxin stimulation. Platelets were stimulated with 10
nM convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times
indicated, fixed, and analyzed by flow cytometry. P values were calculated between time
points indicated; error bars indicate mean ± SD; n = 4-8 experiments for each time point
indicated, using 4 animals.
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Figure 2-5. PD GPVI receptors exhibit delayed Syk phosphorylation and calcium
signaling.
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Figure 2-5. PD GPVI receptors exhibit delayed Syk phosphorylation and calcium
signaling. A. Lentiviral vectors were used to express WT GPVI or PD GPVI or vector
alone (vector) in RBL-2H3 cells, and surface expression of GPVI was detected by flow
cytometry. B. Time course of GPVI-mediated activation of Syk following convulxin
stimulation in WT GPVI and PD GPVI-expressing RBL-2H3 cells. GPVI-expressing
RBL-2H3 cells were stimulated with convulxin for the time periods indicated, and whole
cell lysate was analyzed by immunoblotting (WB) with antibodies against activated Syk
(pSyk) and total Syk. C. Ca2+ mobilization in RBL-2H3 cells expressing WT and PD
GPVI and vector control. Cells were loaded with the Ca2+-sensitive fluorophore Fura-2
AM and stimulated with 1 nM convulxin. Intracellular Ca2+ mobilization was measured
by the ratio of Fura-2 emissions in a fluorimeter. Curves from representative experiments
are shown; n = 3 measurements.
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Figure 2-6. Tracking rolling and adhesion of GFP+/GPVI+ platelets to collagen
under flow.
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Figure 2-6. Tracking rolling and adhesion of GFP+/GPVI+ platelets to collagen
under flow. Measurement of platelet adhesion efficiency during flow over a collagen
coated surface. Shown is an example of sequential images taken with a 75 ms exposure
time during flow of whole blood containing WT GPVI-expressing platelets over a type-I
collagen-coated surface. Blood from reconstituted mice was flowed over a patterned
type-I collagen strip at a shear rate of 1000 s-1, and fluorescent images were taken every
100 ms to follow the interaction of GFP+ platelets with collagen under flow. Each
platelet that appears on the collagen strip was tracked to determine if it remained adherent
(red circles) or did not remain adherent (blue circles). Adhesive efficiency was
determined by a / (a + r), where a = # of platelets that permanently adhere and r = # of
platelets that roll along collagen but do not adhere. The direction of flow and
translocation of platelets is from left to right.
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Figure 2-7. The GPVI PRD is required for efficient platelet adhesion to collagen
under flow.
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Figure 2-7. The GPVI PRD is required for efficient platelet adhesion to collagen
under flow. A. Adhesive efficiency to collagen under flow of WT or PD GPVIexpressing platelets or vector control platelets. B. Rolling times on collagen for WT or
PD GPVI platelets. The time each adherent platelet spent in the rolling phase was
calculated based on the number of frames during which each platelet changed position.
B. (i) Rolling times are shown divided into terciles (1st, shortest third of rolling times in
each group; 2nd, middle third of rolling times in each group; 3rd, longest third of rolling
times in each group). B. (ii) Percentage rolling times < 350 ms, 350–700 ms, and > 700
ms. The same adherent platelets were analyzed in panels (i) and (ii). ** = P < 0.01; error
bars indicate mean ± SD; 3-5 movies using 3-4 animals for each GPVI variant or vector
control were analyzed in a blinded fashion; n = total number of adherent platelets
analyzed.
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Figure 2-8. The GPVI PRD preferentially binds the SH3 domains of the SFKs Lyn
and Hck.
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Figure 2-8. The GPVI PRD preferentially binds the SH3 domains of the SFKs Lyn
and Hck. A. Shown are the amino acid sequences of the cytoplasmic tail of WT GPVI
and PD GPVI expressed as GST-fusion proteins. B. Binding of SH3 domain-containing
proteins from platelet lysate is dependent on the GPVI PRD. Washed human platelets
were lysed, and platelet proteins were precipitated with either GST-WT GPVI or GSTPD GPVI bound to glutathione beads, resolved by SDS-PAGE, and analyzed by
immunoblotting (WB) for Lyn, Fyn, or GST. C. Phage display screening of WT or PD
GPVI GST-fusion protein binding to human SH3 domains, an unbiased method in which
all SH3 domains compete with each other for binding to the target protein. SH3 domainexpressing phages captured by GST-GPVI constructs or plain GST were used to infect E.
coli TG1 cells and plated as 10-fold dilutions onto ampicillin plates. Enrichment of SH3
displaying phages bound to the WT GPVI receptor was approximately 1000-fold
compared to that bound to PD GPVI or GST alone. D. Lyn constitutively associates with
GPVI in unstimulated platelets. Washed human platelets were left unstimulated or
stimulated with 3 nM convulxin for 15 s, lysed, and proteins immunoprecipitated (IP)
with GPVI were resolved by SDS-PAGE and analyzed by immunoblotting (WB) for Lyn,
Fyn, Src, Btk, FcR!, or GPVI. An immunoblot of whole cell lysate (WCL), loaded at 1%
of GPVI IP input, and one of mouse IgG control IP are also shown. Blots depicted are
representative of 3 independent experiments.
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Table 2-I. The GPVI cytoplasmic tail preferentially binds the SFKs Lyn and Hck.

SH3 domain
Lyn
Hck
Fyn
Btk
Yes
Src
CrkL
Intersectin 1 3rd SH3
domain

Screen
#1
4/8
clones
1/8
clones
1/8
clones
1/8
clones
1/8
clones
0/8
clones
0/8
clones
0/8
clones

Screen
#2
10/24
clones
10/24
clones
1/24
clones
1/24
clones
0/24
clones
0/24
clones
1/24
clones
1/24
clones

# of clones
Screen
#3
2/16
clones
8/16
clones
0/16
clones
2/16
clones
2/16
clones
0/16
clones
0/16
clones
2/16
clones

Total
16/48
clones
19/48
clones
2/48
clones
4/48
clones
3/48
clones
0/48
clones
1/48
clones
3/48
clones

Table 2-I. The GPVI cytoplasmic tail preferentially binds the SFKs Lyn and Hck.
The identity of the SH3 domains bound by GST-WT GPVI proteins was determined by
sequencing the inserts of the selected phage clones after a single round of affinity
selection. Shown are sequencing results of bacterial clones containing the phagemide
encoding the corresponding SH3 domain bound to WT GPVI. Results demonstrate GPVI
intracellular tail binding preference for SFKs, specifically Lyn and Hck
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Figure 2-9. GPVI directly activates Lyn and Hck in a PRD-dependent manner.
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Figure 2-9. GPVI directly activates Lyn and Hck in a PRD-dependent manner.
Recombinant Hck (panel A), Lyn (panel B), and c-Src (panel C) were purified from Sf9
insect cells in an inactive state and assayed for kinase activity with a peptide substrate in
vitro in the presence of increasing concentrations of purified GST-WT GPVI, GST-PD
GPVI, or recombinant HIV-1 Nef. Each condition was repeated in quadruplicate, and the
extent of phosphorylation is expressed as mean percent phosphorylation relative to a
control phosphopeptide ± SD. The results shown are representative of 2 independent
experiments.
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Figure 2-10. GPVI-bound Lyn is held in the active state in unstimulated platelets.
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Figure 2-10. GPVI-bound Lyn is held in the active state in unstimulated platelets.
Washed human platelets were left unstimulated or stimulated with 3 nM convulxin for 15
s, lysed, and proteins immunoprecipitated (IP) with GPVI were immunoblotted (WB)
with phosphospecific antibodies for Lyn. pY396 indicates Lyn phosphorylated at the
activation loop, and pY507 indicates Lyn phosphorylated at the negative regulatory site.
Phospho-Lyn Y396 antibody reacts with other SFKs phosphorylated at their activation
loop, but the characteristic doublet at 53 kD and 56 kD identifies Lyn as the predominant
species. Probing with 4G10 was used to detect phosphorylated FcR! chain, compared to
total FcR! chain, that co-immunoprecipitated with GPVI. An immunoblot of whole cell
lysate (WCL), loaded at 1% of GPVI immunoprecipitation input, is also shown. Blots
depicted are representative of 3 independent experiments.
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Figure 2-11. Lyn- and Fyn-deficient platelet activation following convulxin
stimulation.
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Figure 2-11 (cont’d). Lyn- and Fyn-deficient platelet activation following convulxin
stimulation.
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Figure 2-11. Lyn- and Fyn-deficient platelet activation following convulxin
stimulation. A. Platelets from Lyn-/- mice or wild-type littermate controls (WT) were
stimulated with the indicated concentrations of convulxin for 10 min, and P-selectin
expression was determined by flow cytometry. B. Time course of platelet fibrinogen
binding following convulxin stimulation. Platelets were stimulated with 10 nM
convulxin in the presence of Alexa-Fluor 647-conjugated fibrinogen for times indicated,
fixed, and analyzed by flow cytometry. * = P <0.05, ** = P <0.01, *** = P <0.005; error
bars indicate mean ± SD; n = 4-6 experiments using 3 mice of each genotype for each
concentration of convulxin or time point. C. Platelets from fyn-/- mice or wild-type
littermate controls (WT) were stimulated with the indicated concentrations of convulxin
for 10 min, and P-selectin expression was determined by flow cytometry. Bars indicate
% P-selectin positive platelets. D. Time course of platelet fibrinogen binding following
convulxin stimulation. Platelets were stimulated with 10 nM convulxin in the presence of
Alexa-Fluor 647-conjugated fibrinogen for times indicated, fixed, and analyzed by flow
cytometry. Bars indicate mean fluorescent intensity (MFI) of fibrinogen binding. * = P
<0.05, ** = P <0.01, *** = P <0.005; error bars indicate mean ± SD; n = 4-6 experiments
using 3 mice of each genotype for each concentration of convulxin or time point.
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Figure 2-12. Lyn-deficient platelets exhibit defective adhesion to collagen under
flow.
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Figure 2-12. Lyn-deficient platelets exhibit defective adhesion to collagen under
flow. A. Blood from Lyn-/-, Fyn-/-, or wild-type control animals was flowed over a
patterned type-I collagen strip at a shear rate of 1000 s-1. Images depict adhesion of
fluorescently labeled platelets after 5 min of flow. The direction of flow is from left to
right. B. Quantitation of percent of surface area coverage following 5 minutes of flow.
*** = P < 0.005 for surface area coverage between WT and Lyn-/- platelets and between
Fyn-/- and Lyn-/- platelets; error bars indicate mean ± SD; n = 6-8 experiments using 4
mice of each genotype.
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Figure 2-13. Priming of Lyn by the GPVI PRD drives rapid signal transduction
following receptor ligation.

Figure 2-13. Priming of Lyn by the GPVI PRD drives rapid signal transduction
following receptor ligation. In this model, Lyn is held in an activated state when
constitutively bound to GPVI through displacement of the Lyn SH3 domain (light green)
by the GPVI PRD (light red). Premature, ligand-independent receptor signaling is
prevented by sequestration of the GPVI-associated FcR! chain (dark green) within the
lipid bi-layer, keeping ITAM domains (light blue) inaccessible to activated Lyn prior to
receptor ligation112. Following GPVI-collagen binding, the FcR! chain is released from
the membrane by clustering or mechanical shear forces, allowing GPVI-bound, activated
Lyn to phosphorylate the FcR! ITAM. ITAM phosphorylation results in recruitment of
Syk (purple) and initiation of the downstream GPVI signaling cascade.
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Chapter 3—In contrast to mammalian platelets, avian thrombocytes do not form
aggregates on collagen under arterial flow conditions

Summary
Specific cellular and molecular mechanisms exist within platelets to orchestrate the
coordinated action of aggregate formation over collagen during hemodynamic flow. Both
mammals and birds have high-pressure vascular systems, with similar flow rates and
fluid shear forces. In birds, nucleated thrombocytes that are 3-5 times the diameter of
platelets, and approximately 10-fold less numerous, are believed to play a hemostatic role
analogous to that of platelets. However, it is unknown whether avian thrombocytes
mediate aggregate formation under high shear in a manner similar to platelets. Using
transcriptional profiling, we find that avian thrombocytes express most of the signaling
receptors and pathways described in platelets. Flow of PPACK-anticoagulated chicken
whole blood over chicken collagen at high shear results in thrombocyte rolling and firm
adhesion, but thrombocytes covered significantly less surface area compared to human
platelets and failed to form 3-dimensional aggregates. We describe molecular differences
between platelets and thrombocytes that may explain the inability of thrombocytes to
form aggregates under flow and suggest that vaso-occlusive arterial thrombosis may be a
uniquely mammalian phenomenon that provided an evolutionary advantage in response
to trauma but now underlies the basis of human cardiovascular disease and death.
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Introduction
Acute myocardial infarction results from coronary artery occlusion by a platelet thrombus
formed under high shear, most often following rupture of a nonstenotic atherosclerotic
plaque5,6. Platelet-driven thrombosis is especially important in the arterial system,
particularly in the high shear environment of stenotic coronary arteries 1,120. Platelet
aggregate formation under hemodynamic shear is highly efficient, and inhibiting this
process is a basis for treatment of cardiovascular disease. Improved understanding of the
pathological mechanisms underlying platelet aggregate formation at the site of vessel
injury will advance our knowledge and treatment of cardiovascular disease.
The mechanisms by which platelets adhere and aggregate under hemodynamic
conditions are essential for mammalian hemostasis and thrombosis and have been
exceptionally well studied85. Hemostasis, the cessation of bleeding, is a requirement of
any organism that utilizes blood circulation for tissue oxygenation and removal of waste
products. All essential mammalian blood coagulation factors are conserved in primitive
non-mammalian vertebrates such as zebrafish121. While hemostasis is a necessity to
mammalian and non-mammalian species alike, megakaryocytes and non-nucleated
platelets are exclusive to mammals. All other vertebrates have nucleated thrombocytes,
instead of platelets, as hemostatic effector cells. Significantly less is understood of the
function of thrombocytes, compared to that of platelets.
Thrombocytes found in non-mammalian vertebrates are nucleated, ovoid-shaped,
and formed from diploid precursors in the bone marrow. Unlike more primitive
vertebrates, such as the zebrafish or reptilian species, avian species have a highly
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developed cardiovascular system with a high cardiac output and blood pressures that can
exceed those in mammalian systems122. Therefore, the hemodynamic forces that
necessitate efficient hemostasis in mammals must also be present in birds. Circulating
thrombocytes are larger than platelets and similar in size to lymphocytes, about 6-8 µm in
diameter. In chicken blood, there are approximately 20-60,000 thrombocytes per µL, a
significantly lower concentration than that of mammalian platelets123,124.
The function of thrombocytes in serving as specialized hemostatic cells is
believed to be analogous to that of platelets, but evidence in support of this claim is
limited and consists almost entirely of in vitro data. Avian thrombocytes express #2b$3
integrin and aggregate through binding plasma fibrinogen in response to thrombin and 5HT stimulation125-127. In contrast to platelets, thrombocytes have not been demonstrated
to aggregate in response to ADP or epinephrine, although ADP may cause thrombocyte
shape change125,128. Thrombocytes secrete granule contents, including 5-HT, following
stimulation and contain a surface-connected canalicular system membrane component,
also found in platelets129-131. Additionally, thrombocytes actively phagocytose Grampositive and -negative bacteria and have been proposed to serve a broader immunologic
function compared to that of platelets124,132.
The fact that megakaryocytes and platelets are unique to mammals suggests there
is some important aspect of mammalian biology and evolution—perhaps the need for
more efficient hemostasis in response to trauma—that benefitted from the use of
platelets, compared to thrombocytes, as hemostatic cells. However, if this hypothesis is
correct—that platelets confer a superior hemostatic response to the organism—then what
87

functions of platelets are exceptional and cannot be performed by thrombocytes? It is
intriguing that platelets are not required for any known element of hemostasis that is only
found in mammals.
The existence of thrombocytes in avian species with high-pressure vascular
systems presents an opportunity to test the conservation of basic elements of cellular
hemostasis between platelets and thrombocytes. Our initial interest in avian thrombocyte
biology began from the finding that thrombocytes do not contain an ortholog of the
platelet collagen receptor glycoprotein (GP) VI detectable by BLAST search (see Chapter
2), while many other platelet-specific receptors have definitive chicken orthologs. We
were surprised to discover studies demonstrating that chicken thrombocytes aggregate in
response to collagen, a GPVI-dependent process in mammals127,130. Through collageninduced platelet activation, GPVI is required for the transition of a rolling platelet to a
firmly adherent platelet during flow on a collagen surface (see Chapter 1). Our findings
in the previous chapter demonstrate that GPVI is molecularly specialized to rapidly
activate platelets under conditions of hemodynamic flow. Can thrombocytes also activate
and firmly adhere to collagen under arterial shear conditions?
Using transcriptional profile analysis, we determine that thrombocytes
specifically express the receptors associated with hemostatic function and shear-resistant
adhesion in platelets. Signaling studies confirm that thrombocytes are potently activated
by collagen. Collagen signaling in the thrombocyte uses an immune receptor pathway
analogous to that of GPVI. During flow of chicken whole blood in the presence of
thrombin inhibition, we observe thrombocyte rolling and integrin-dependent firm
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adhesion. However, there is significantly less surface coverage compared to that
exhibited by platelets and a striking absence of 3-dimensional aggregate formation. We
demonstrate that specific molecular mechanisms that have been adopted by the platelet to
promote aggregate formation under shear, such as a high density of #2b$3 integrin, are
absent in the thrombocyte. These studies suggest that the ability to rapidly form 3dimensional aggregates under arterial shear is exclusive to platelets. Platelet-mediated
occlusive thrombus formation may represent a distinct quality of mammalian hemostasis
not present in other species that also have a high-pressure system.
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Results
Chicken thrombocytes specifically express genes associated with platelet function.
Thrombocytes in avian species are believed to express many platelet-specific proteins
and function analogously to platelets in mammalian systems, yet a thorough
transcriptional profile analysis has not been performed. We wished to complete a geneexpression profile analysis of chicken thrombocytes to determine if they contain
transcripts associated with hemostatic function and if this expression is restricted only to
thrombocytes. Based on their expression of #2b$3 integrin, thrombocytes could be
isolated from chicken plasma preps by staining with AP-2 mAb, which cross-reacts with
both chicken and human #2b$3123 (Fig. 3-1A). On average, chicken plasma preps
contained about 50-70% thrombocytes, with the rest presumably representing leukocytes
(Fig. 3-1A). Using cell sorting based on positive and negative cell markers, we isolated
pure populations of chicken thrombocytes and lymphocytes (Fig. 3-1B). Geneexpression analysis on the Affymetrix chicken chip revealed that thrombocytes, and not
lymphocytes, significantly upregulate genes that are known to have a specific role in
platelet function, including the VonWillebrand factor receptors GPIb and GPIX, integrins
$1, $3, #2, and #V, the thrombin receptor protease-activated receptor (PAR) 1, the ADP
receptors P2X1 and P2Y1, and the serotonin receptor HTR2A (Table 3-I). The fact that this
list was not exhaustive for platelet genes is at least partially due to incomplete annotation
of the chicken genome and/or lack of representation on the Affymetrix chicken gene chip.
These limitations notwithstanding, transcriptional profile analysis confirms that chicken
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thrombocytes are specialized among hematopoietic cells to serve a hemostatic function in
the organism.

Chicken thrombocytes are strongly activated by thrombin and collagen.
In vivo, following vessel injury, thrombin from tissue factor release and collagen
exposure in the subendothelium are the two primary activators of platelets (see Fig. 1-1).
We sought to determine if thrombocytes are capable of activation in response to these
agonists and how the thrombocyte response compares to that of platelets. Due to a lack
of species-specific activation markers for chicken thrombocytes, we performed [3H]
serotonin (5-HT) secretion assays under non-stirring conditions as a means to directly
compare the activation response of platelets and thrombocytes. Chicken thrombocytes
readily take up 5-HT from the plasma and release it upon activation, presumably through
a degranulation mechanism similar to that of platelets129,130. Thrombin stimulated [3H]5HT release in a concentration-dependent manner, although this stimulation was less
potent than that of human platelets (Fig. 3-2A). The thrombin used in this assay was
purified from a bovine source, and it is not clear if species-specific differences account
for the lower sensitivity of chicken thrombocytes.
A gene encoding the platelet-specific collagen receptor GPVI was absent from
our gene-expression analysis, and a BLAST search revealed no GPVI orthologs in the
chicken genome. However, it has been documented that chicken thrombocytes are
capable of aggregating in response to collagen, although the relative strength of collagen
as a thrombocyte agonist is unclear130. Fibrillar equine type-I collagen induced [3H]5-HT
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release from thrombocytes in a concentration-dependent manner, and this response was
even more sensitive than that of human platelets (Fig. 3-2B). However, consistent with
the apparent lack of GPVI on chicken thrombocytes, thrombocytes were not activated by
convulxin and only very weakly activated by collagen-related peptide (CRP), both of
which are GPVI-specific agonists that induced potent activation of platelets (Fig. 3-2C).
It has been unclear the extent to which ADP or thromboxane, both of which are
well characterized platelet agonists, can activate avian thrombocytes. ADP did not
induce any [3H]5-HT release in either thrombocytes or platelets (Fig. 3-2C), consistent
with data demonstrating a lack of ADP-induced secretion in platelets in the absence of
aggregation, when assays are performed in non-stirring conditions133. Thrombocyte
activation was also determined by the ability of agonists to induce aggregation of
thrombocytes in thrombocyte-rich blood plasma. Collagen induced thrombocyte
aggregation, whereas ADP and the thromboxane analog U-46619 at high pharmacologic
concentrations induced only transient and weak thrombocyte aggregation (Fig. 3-2D). 5HT, which has been reported to induce duck thrombocyte aggregation, did not induce any
aggregation response in chicken thrombocytes at high pharmacologic doses (Fig. 32D)127. Annexin V and human fibrinogen binding following stimulation of washed
thrombocytes was analyzed by flow cytometry but could not produce a readout of
thrombocyte stimulation (data not shown).
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Collagen-induced signaling in the thrombocyte requires Src-kinases and Syk.
Unlike most activating receptors on the platelet surface, which are G-protein coupled,
GPVI is a member of the immunoglobulin (Ig) domain-containing superfamily and
utilizes tyrosine kinase signaling through Src-family kinases (SFKs) and Syk kinase (see
Fig. 1-2)46. To determine if collagen-induced thrombocyte activation is also dependent
on these tyrosine kinases, we measured the ability of the SFK inhibitor PP2 and the Sykinhibitor piceatannol to inhibit collagen-induced [3H] 5-HT release. Both PP2 and
piceatannol inhibited collagen-induced thrombocyte [3H] 5-HT release in a dosedependent fashion (Fig 3-3A and B) and were more selective for inhibiting collageninduced, but not thrombin-induced, secretion (Fig. 3-3C). Interestingly, PP2 was
observed to partially inhibit thrombin-induced [3H] 5-HT release in the thrombocyte,
whereas it had no affect on thrombin activation of platelets (Fig. 3-3C).

Thrombocytes do not form aggregates on a collagen surface under arterial shear
conditions.
The ability of platelets to adhere and form aggregates when exposed to collagen under
high shear and the cellular and molecular mechanisms underlying this process have been
thoroughly characterized (see Fig 1-3). It is unknown whether thrombocytes, which
would be subject to much greater shear forces proportional to the square of their
diameter—9-25 times the forces on platelets—are capable of this function. The fact that
thrombocytes express the GPIb/V/IX complex and the high-affinity collagen receptor
integrin #2 suggested that vWF-mediated rolling and integrin-mediated adhesion may be
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conserved. To test whether thrombocytes are capable of rolling, adhering, and
aggregating on a collagen surface under high shear, we perfused chicken and human
whole blood anticoagulated with the direct thrombin inhibitor PPACK over a chicken
collagen surface. Chicken type-I and III collagen was purified from chicken skin and the
resultant collagen-coated slides had a more heterogeneous collagen distribution than
slides coated with the commercially available Chronolog type-I collagen derived from
equine tendon (Fig 3-4). We used chicken collagen for the hemodynamic flow assays to
avoid any possible species-specific effects of the collagen type on thrombocyte adhesion
under flow.
These flow assays reproduce a critical element of platelet-collagen interaction in
vivo—the need to adhere firmly to immobilized collagen under hemodynamic shear—but
isolate the function of collagen-induced platelet activation by excluding thrombin
generation and endothelial cell contribution (see Fig. 1-3). To allow for real-time
fluorescent imaging of adherent cells, platelets and thrombocytes were labeled with the
mouse mAb AP-2, which binds both human and chicken #2b$3123. AP-2 blocks
fibrinogen binding by up to 50% in human platelets when used at high concentrations but
appears to have only a minor effect on thrombocyte-fibrinogen binding129,134. AP-2 does
not inhibit thrombocyte aggregation in response to thrombin123,126. During flow of
human blood over collagen, platelets rolled and firmly adhered, and after 5 min of
perfusion, large 3-dimensional aggregates had formed on the collagen surface
(Supplemental movie 3-1). Perfusion of chicken whole blood revealed thrombocytes
rolling and firmly adhering to the collagen surface, and membrane tethers could be
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observed (Supplemental movie 3-2). After 5 min of perfusion, a large number of
thrombocytes had firmly adhered but covered a much smaller total collagen surface area
compared to platelet coverage (Fig. 3-5). Most profoundly, thrombocytes were not
observed to form any aggregates on the collagen surface, whereas platelets formed large
aggregates in a shear-dependent fashion, consistent with previous findings (Fig. 3-5BD)40.
To determine if thrombocytes are capable of aggregate formation if given more
time to set down adherent cells, chicken blood was perfused over collagen for 15 min.
Remarkably, after 15 min, a monolayer composed of more thrombocytes than observed in
5-min perfusion experiments had formed on the collagen surface, but virtually no 3dimensional aggregates had formed (Fig. 3-6). The lack of 3-dimensional aggregate
formation by thrombocytes was most evident in DAPI-stained images that detect each
thrombocyte nucleus. While thrombocytes might be closely approximated to one
another, and in some cases were in direct contact with one another, there was no overlap
of individual nuclei, suggesting that no cells were stacked on top of each other (Fig. 36B). Together, these results suggest that thrombocytes have a conserved mechanism to
adhere to collagen under arterial shear, but unlike platelets, they do not cover a collagen
surface as efficiently and do not form aggregates under hemodynamic flow conditions.
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Thrombocytes are fully activated despite a lack of aggregate formation under
hemodynamic flow.
Platelet adhesion and aggregate formation under flow are associated with a flattening of
the platelet shape and formation of filopodia and lamellipodia. The spreading of fully
activated platelets presumably facilitates aggregate formation by allowing for more
efficient stacking of platelets on top of each other. To determine if thrombocytes are
fully activated and undergo a similar shape change during aggregate formation, we
performed scanning electron microscopy of platelets and thrombocytes following a 5-min
perfusion of whole blood over chicken collagen through the parallel plate flow chamber.
High-power imaging confirmed that thrombocytes covered significantly less surface area
compared to platelets and did not form 3-dimensional aggregates (Fig. 3-7A and B).
Large, 3-dimesnsional aggregates were readily observed for platelets following whole
blood perfusion under the same conditions (Fig. 3-7A and B). Individual thrombocytes
and platelets appeared fully activated, as evidenced by cell spreading, accompanied by
filopodia and lamellipodia formation and cell vacuolization, which suggested
thrombocyte degranulation (Fig. 3-7C). Occasional cell-cell contacts between
thrombocytes could be observed, presumably a result of membrane extensions and
fibrinogen-mediated thrombocyte cross-linking (Fig. 3-7B and E). In contrast, platelet
cross-linking was extremely robust, resulting in large aggregates and creation of a platelet
lattice (Fig. 3-7D).
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Pharmacologic inhibition of integrin function or collagen signaling decreases
thrombocyte adhesion to collagen under flow.
Integrin activation is required to mediate firm adhesion to collagen under flow. To assess
the requirement for integrins to mediate adhesion of thrombocytes, we used EDTA to
chelate cations required for integrin function. EDTA inhibited thrombocyte and platelet
adhesion to collagen, suggesting that collagen-induced activation of integrins under shear
is a conserved process (Fig. 3-8A).
Collagen-induced platelet activation through GPVI signaling is required for
normal platelet adhesion to collagen under hemodynamic flow, and pharmacologic
inhibition or genetic deletion of GPVI significantly reduces platelet adhesion under
shear40. To test whether collagen-induced thrombocyte activation is required for
adhesion under shear, we used PP2 to inhibit collagen-mediated signaling. Following 5min perfusion of whole blood pre-treated with PP2, both platelet and thrombocyte surface
coverage of collagen was reduced to a similar degree (Fig. 3-8B and Supplemental
movies 3-3 and 3-4). Following PP2 treatment, both platelets and thrombocytes
demonstrated an increased amount of rolling along the collagen surface, with delayed or
absent firm adhesion to collagen (Supplemental movies 3-3 and 3-4). These results
suggest that for both platelets and thrombocytes, collagen-induced signaling under
hemodynamic flow is required for cellular activation and efficient transition from a
rolling state to a firmly adherent state.
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Thrombocytes express fewer # 2b$ 3 integrin receptors than do platelets and are not
affected by # 2b$ 3 inhibition during adhesion to collagen under flow.
The observation that thrombocytes do not form aggregates under hemodynamic flow
could be expected if thrombocytes were to express significantly lower levels of #2b$3
integrin on the cell surface. #2b$3 is the most abundant platelet surface receptor,
expressed at a copy number of approximately 50-80,000 receptors per cell, and, as a
result, is found at an extremely high density on the cell surface135. To compare the levels
of #2b$3 on the surface of human platelets to that on the surface of chicken thrombocytes,
we compared staining with AP-2 mAb by flow cytometry. Remarkably, the expression
of #2b$3 on the platelet surface was significantly greater than that on the thrombocyte
surface (MFI 653 on platelets compared to 322 on thrombocytes; P = 0.018) (Fig. 3-9A).
Taking into account a conservative estimate of thrombocyte versus platelet size—
assuming a platelet diameter of 2 µm and a thrombocyte diameter of 6-7 µm—and
assuming a spherical shape for both cells, a thrombocyte could be expected to have a
surface area at least 9-12.25 times that of a platelet. This difference in surface area would
result in an 18.2-24.8 times greater density of #2b$3 on the platelet compared to the
thrombocyte.
To test the importance of #2b$3 in platelet and thrombocyte responses to collagen
under hemodynamic flow, we pharmacologically inhibited #2b$3 with eptifibatide, a
cyclic lys-gly-asp peptide that prevents #2b$3 binding to fibrinogen136. Eptifibatide
inhibited collagen-induced aggregation of thrombocytes (Fig. 3-9B). After 5 min of
perfusion of eptifibatide-treated whole blood, platelet surface coverage of collagen was
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dramatically reduced at high shear forces of 1300 and 1150 s-1 yet was paradoxically
increased at lower shear forces of 700-350 s-1 (Fig. 3-9Ci). Eptifibatide treatment had no
effect on thrombocyte adhesion to collagen under flow (Fig. 3-9Cii and Supplemental
movie 3-6). By blocking platelet aggregation, eptifibatide treatment resulted in
deposition of single platelets only and the absence of platelet aggregates (Fig. 3-9D and
Supplemental movie 3-5). Pharmacological inhibition of #2b$3 on platelets resulted in a
monolayer formation on the collagen surface analogous to normal thrombocyte adhesion
following whole blood perfusion. These results demonstrate that at high shear forces,
platelets are dependent on aggregate formation to maximize surface coverage of collagen,
whereas thrombocytes do not utilize aggregate formation to enhance surface coverage
under hemodynamic flow.

Platelets, but not thrombocytes, utilize ADP signaling to enhance adhesion and
aggregate formation under hemodynamic flow.
ADP, released from platelet dense granules during collagen activation under flow,
promotes aggregate formation through autocrine and paracrine activation of P2Y
receptors137,138. While ADP treatment only resulted in weak and transient thrombocyte
aggregation, this response was inhibited with the small molecule P2Y12 antagonist
MesAMP (Fig. 3-10A). Consistent with previously published findings, treatment of
whole blood with MesAMP decreased platelet surface coverage and aggregate size
following 5-min perfusion over collagen (Fig. 3-10B). MesAMP did not decrease
collagen surface coverage of thrombocytes under flow (Fig. 3-10C), consistent with
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thrombocytes’ apparent lack of a robust ADP-mediated activation response. These
findings confirm that platelets utilize ADP signaling to enhance aggregate formation and
surface coverage on collagen under flow, while they suggest that thrombocytes do not
employ this positive-feedback mechanism to enhance shear-resistant adhesion.
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Discussion
The aggregation of platelets in response to collagen exposure following vascular injury
allows for an efficient hemostatic response but also underlies the thrombotic
pathophysiology of acute cardiovascular disease. While anuclear platelets are
responsible for cellular hemostasis in mammals and pathological thrombosis in humans,
avian species circulate larger, nucleated thrombocytes, which are believed to serve a
similar hemostatic function in birds. The ability of thrombocytes to respond to collagen
under hemodynamic flow has not been studied. In this chapter, we demonstrate that
while thrombocytes are capable of potent activation by collagen and firm adhesion to
collagen under flow, thrombocytes, in contrast to platelets, do not form 3-dimensional
aggregates under arterial flow conditions. We provide evidence that this profound
difference is due to the relatively low density of #2b$3 receptors on the thrombocyte
surface and the lack of additional positive-feedback pathways that are required for
maximal platelet surface coverage and aggregate formation.
True anuclear platelets first appeared in early mammalian species. The
monotreme order, most closely related to primitive mammalian ancestors, consists of
egg-laying mammals such as the duck-billed platypus and the echidna (spiny anteater).
These species contain platelets of size and number similar to those found in mice and
humans, although monotreme platelets may occasionally be larger than human or mouse
platelets—up to 8 µm in diameter, similar in size to a thrombocyte7. Marsupial species
such as the opossum have platelet counts that are comparable to those of placental
mammalian species. One common misconception is the idea that placental birth was the
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driving force behind the evolution of platelets. The fact that monotremes, which are egglaying, and marsupials, which have a nonplacental pregnancy, both have platelets
suggests that platelets did not evolve to facilitate placental birth.
There is functional evidence that, as the major constituent of circulating cells after
red blood cells, thrombocytes function as the hemostatic effector cells in non-mammalian
vertebrates. However, gene expression profiling of thrombocytes has not been performed
to demonstrate that thrombocytes specifically upregulate platelet-specific genes
associated with hemostatic function. Our results show that, compared to lymphocytes,
thrombocytes specifically express genes that have a distinct role in platelet function. The
fact that we limited our comparison of thrombocytes solely to lymphocytes does not
eliminate the possibility that other blood cells such as granulocytes or monocytes could
express hemostatic effector genes. However, the fact that the K55-negative / AP-2
negative population was relatively minor suggests that this cell population could not be
contributing in large numbers to avian hemostasis. Additionally, all adherent cells
following flow on the collagen surface expressed #2b$3, as determined by AP-2 binding,
suggesting that only thrombocytes are capable of this specialized shear-resistant
behavior. In summary, our results demonstrate that avian thrombocytes have a gene
expression profile associated with hemostatic function.
Results from parallel plate flow chamber experiments suggest that thrombocytes
do not effectively form shear-resistant aggregates during flow over a collagen surface.
This finding represents a fundamental difference from the behavior of platelets, which,
even in the absence of thrombin generation, form large 3-dimensional aggregates on
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collagen in a shear-dependent fashion. What are the mechanisms that underlie this
distinction? In flowing blood, thrombocytes are subject to greater forces due to their
larger cell size, proportional to the square of their diameter. A thrombocyte of 7 µm in
diameter could be subject to 12.25 times greater force compared to a platelet of 2 µm in
diameter. This increased force could negatively affect the ability of thrombocytes to
build a growing aggregate in the setting of flowing blood.
We attempted to address cellular and molecular mechanisms underlying this
distinction in shear-resistant aggregate formation. Thrombocytes have a ~50% reduction
in #2b$3 copy number on the cell surface, which results in an approximately 10-20-fold
decrease in #2b$3 density, after taking the larger thrombocyte size into account. The
fibrinogen receptor, integrin #2b$3, is expressed at approximately 80,000 copy numbers
on the platelet surface, resulting in a high density which accounts for 17% of the platelet
membrane protein mass139. Thrombocytes have sufficient #2b$3 density to mediate
aggregation under stirring conditions, but greater densities, such as those found on
platelets, may be required for aggregation under the more stringent conditions of
hemodynamic flow at arterial shear rates. This difference in integrin density between
platelets and thrombocytes could underly the major distinction in aggregation behavior
during flow over collagen. It would be intriguing to overexpress #2b$3 in the chicken
thrombocyte to see if increased integrin expression at densities similar to that of the
platelet could allow for shear-resistant thrombocyte aggregation in whole blood flow.
Although they are nucleated cells, thrombocytes are reported to be extremely difficult to
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culture, posing an impediment to gene transfection and reconstitution of chicken blood
with cultured thrombocytes140.
Similar to platelets, thrombocytes appear fully activated, spread, and degranulated
in response to collagen under flow, a prerequisite for platelet aggregation under these
conditions. The difference in cell size is the only major distinction between these two
cell types as seen under high-power scanning electron microscopy analysis.
Thrombocytes engage in robust cell spreading behavior, characterized by filopodia and
lamellipodia formation, in a manner almost identical to platelets, suggesting evolutionary
conservation of this response and an essential role for it in normal hemostatic function.
It appears that thrombocytes may have a less extensive and/or less sensitive
repertoire of agonists involved in potentiating thrombocyte activation. While thrombin
and collagen are both primary activators of thrombocytes and platelets, platelets utilize
positive feedback via thromboxane and 5-HT signaling to maintain activation, and, most
notably, they absolutely require ADP signaling to maximize adhesion to collagen under
flow137,138. Thrombocytes do not appear to have evolved a potent response to any of
these agonists. The possible existence of additional agonists, perhaps unique to
thrombocytes and not platelets, cannot be ruled out. Such agonists may serve to augment
thrombocyte activation following thrombin or collagen stimulation. However, in the
absence of a high density of #2b$3 integrin and the potential for aggregation under high
shear, robust autocrine and paracrine signaling during adhesion under flow may not have
any additional effect. It is possible that the adaptations that facilitate platelet aggregation
under arterial blood flow conditions—small cell size, increased cell number, high #2b$3
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density—co-evolved with positive-feedback pathways, such as a robust response to ADP,
that potentiate platelet aggregation.
The finding that chicken thrombocytes do not form aggregates over collagen
following blood flow at arterial shear rates raises the question of what happens in birds
following vascular injury. It has been repeatedly demonstrated in mammalian injury
model systems, most well characterized in the mouse, that vascular injury of a sufficient
degree results in the formation of a platelet-mediated thrombus that occludes vessel flow.
Our results from chicken thrombocyte studies raise several questions. Is cell-mediated
thrombosis strictly a platelet, and therefore, mammalian phenomenon? Do birds form
thrombi following vessel wall injury, and, if so, are there alternate mechanisms for this
response other than thrombocyte aggregation, such as a robust coagulation response?
Finally, is occlusive thrombus formation absolutely necessary to prevent hemorrhage
following vascular injury, or is a cell monolayer sufficient for hemostasis in this setting?
Thrombocytes appear capable of monolayer formation following adhesion to collagen
under flow, and perhaps this response is suitable for hemostasis in avian species. The
mammalian adaptation of platelet-driven occlusive thrombus formation is most likely an
adaptive response to significant vessel trauma designed to prevent catastrophic
hemorrhage. However, this response is also the driving force behind pathologic
thrombosis that occurs in the setting of cardiovascular disease. To answer these
questions, comparative thrombosis experiments need to be designed in an avian model to
determine the response of thrombocytes to vessel injury in vivo in the arterial system.
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The hemodynamics and cardiovascular physiology of many non-mammalian
species, such as reptiles and fish, is vastly different from that of mammals, making it
difficult to predict the requirement for an efficient cellular hemostatic response. Avian
species, however, are warm-blooded, with a large cardiac output and higher blood
pressures than mammalian species122. In this sense, the presence of high-shear arterial
flow reproduces a hemodynamic environment very similar to that of a mammalian
system. Some of the most recently characterized thrombocytes are those present in
zebrafish and have been shown to activate in response to collagen and weakly activate in
response to ADP—an activation profile similar to that of chicken thrombocytes141-143.
Additionally, laser injury models of the caudal artery in 3- to 4-day post-fertilization
zebrafish larvae demonstrate generation of thrombocyte aggregates, and, in some cases,
occlusive thrombi143,144. However, the arteries in these zebrafish models are small and
have relatively low shear compared to large arteries found in avian or mammalian
species. Morpholino-injected knockdown of #2b only resulted in a 50% reduction in
thrombus surface area in this model, whereas at arterial shear rates of 1300 s-1,
eptifibatide-treated human platelets show a >90% reduction in aggregate surface area
(Fig. 3-8D)144.
Our finding that potent collagen-induced activation of hemostatic cells is
conserved from platelets to thrombocytes indicates the importance of subendothelial
collagen as a primary activator in hemostasis. However, our studies suggest some
fundamental differences between collagen-induced thrombocyte activation and GPVIinduced platelet activation in response to collagen. Thrombocytes are not activated by
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the GPVI-specific ligands CRP, a collagen peptide mimetic, or convulxin, a snake venom
toxin that binds a site of GPVI not required for collagen interaction. CRP is a synthetic
peptide consisting of 10 gly-pro-hydroxypro (GPO) repeats, cross-linked to create a
quaternary structure28. CRP is believed to specifically activate GPVI through
coordination with certain basic residues exposed within an apical groove in the GPVI D1
ectodomain and is believed to recapitulate the primary mechanism by which GPVI
interacts with collagen23,25,145,146. The fact that CRP does not activate chicken
thrombocytes suggests that the primary means by which collagen interacts with its
receptor(s) on thrombocytes is fundamentally different from that of the collagen-GPVI
interaction. It should be noted, however, that there are residues implied in collagen
binding that have no effect on CRP binding, suggesting the GPVI binding sites for
collagen and CRP are not entirely identical.
The use of tyrosine kinase signaling for collagen-induced activation appears to be
conserved from avian thrombocytes through mammalian platelets. A thrombocytespecific Ig-receptor that couples to the immunotyrosine activating motif-containing FcR!
subunit through a transmembrane arginine has been identified that binds chicken IgY147.
It remains to be seen whether there is a single Ig-receptor or multiple receptors that are
responsible for collagen-induced thrombocyte activation and if unique extra- or
intracellular features of such receptors are conserved through mammalian GPVI.
The lack of a chicken GPVI ortholog is consistent with our understanding that
monotremes (egg-laying mammals), which diverged from therian (marsupial and
placental) mammals approximately 150 million years ago and whose genome is
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particularly well annotated, also do not contain a GPVI ortholog. Furthermore, the
leukocyte-receptor complex (LRC), the gene cluster that encodes mammalian GPVI and
other immunoglobulin (Ig) superfamily members, has undergone dramatic rearrangement
from avian to monotreme to placental mammals114,148-150. Chicken and mammalian
paired Ig-receptors share basic structural similarities and ITAM-coupling mechanisms,
but no direct chicken orthologs exist for mammalian LRC genes114,151. It will be
informative to determine the array of thrombocyte-specific Ig receptors and their role in
hemostatic function.
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Materials and methods
Antibodies and reagents
Mouse AP-2 mAb was a generous gift from Thomas Kunicki123. Mouse K55 mAb was a
generous gift from Hyun Lillehoj152. Convulxin, type-I fibrillar collagen derived from
equine tendon, and ADP were obtained from previously described sources153. Collagenrelated peptide (CRP) was generous gift from Debra Newman. Thrombin from bovine
plasma (40-300 NIH units/mg protein) was purchased from Sigma-Aldrich (St. Louis,
MO). PP2 and piceatannol were purchased form Calbiochem (San Diego, CA).
Eptifibatide was purchased from Merck (Whitehouse Station, NJ). MesAMP was
purchased from Axxora (San Diego, CA). Alexa-Fluor 488 and 647 Monoclonal
Antibody Labeling Kits and Alexa-Fluor 594-conjugated phalloidin were purchased from
Molecular Probes (Carlsbad, CA).

Blood collection and preparation
Chicken studies
Blood was collected from the wing vein of healthy female Rhode Island red pullet
chickens, aged approximately 6 months, from a commercial source using a 19-gauge
butterfly needle into 10-mL or 30-mL syringes anticoagulated with either 1:10 (v/v)
93µm D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (PPACK) or 1:6 (v/v)
acid/citrate/dextrose (65 mM Na3citrate•2H2O, 70 mM citric acid•H2O, 100 mM
dextrose, pH 4.4) or 1:9 (v/v) sodium citrate (130 mM Na3citrate•2H2O, pH 7.4). Whole
blood was diluted 1:1 in modified Tyrode’s buffer (137 mM NaCl, 20 mM HEPES, 2.7
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mM KCL, 3.3 mM NaH2PO4, 5.6 mM glucose, 1 g/L BSA, pH 7.4) containing 1 mM
MgCl2, and 12-mL aliquots were spun at 50 g for 5 min. The thrombocyte-rich plasma
layer was isolated by aspiration pipetting. For preparation of washed thrombocytes, 1
U/mL apyrase and 1 µM prostacyclin were added to thrombocyte-rich plasma, and
samples were washed once in platelet wash buffer (10 mM HEPES, 1 mM EDTA, 150
mM NaCl, pH 6.0) before resuspending in modified Tyrode’s buffer. Cells were counted
using a hemocytometer, and the larger, ovoid red blood cells were deliberately not
counted.
Human studies
Blood was collected from 6 healthy donors using a 19-gauge butterfly needle into 10 mL
or 30 mL syringes anticoagulated as described above. Washed platelets were prepared
are described for thrombocytes above.

Chicken plasma cell transcriptional profiling
Washed thrombocyte-rich plasma from 3 separate chicken blood collections was costained with Alexa-Fluor 488-conjugated K55 mAb and Alexa-Fluor 647-conjugated AP2 mAb for 30 min, washed with phosphate-buffered saline, and resuspended in
Dulbecco’s Modified Eagle Medium (Invitrogen, Carlsbad, CA) at 40 x 107 cells per mL.
2 x 106 K55 positive, AP-2 negative cells (lymphocytes) and K55 negative, AP-2 positive
cells (thrombocytes) were collected via cell sorting, and RNA was isolated using Trizol
(Invitrogen) and RNAEasy Kit (Qiagen, Valencia, CA). Thrombocyte and lymphocyte
cDNA was produced using the Superscript® First Strand Synthesis Kit (Invitrogen).
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Transcriptional profiling was performed by the University of Pennsylvania Microarray
Facility using the GeneChip Chicken Genome Array (Affymetrix, Santa Clara, CA).

[3H] 5-HT secretion assays
Thrombocyte-rich plasma or platelet-rich plasma was incubated with [3H] 5-HT (2 !Ci
[0.074 MBg]/mL) at 37 °C for 30 min. Thrombocyte or platelet suspensions were
washed and resuspended to final concentration of 2 x 107 cells per mL or 2 x 108 platelets
per mL, respectively, in modified Tyrode’s buffer plus 1 µm imiprimine and 1 mM
CaCl2. Cell aliquots of 500 mL were stimulated under non-stirring conditions at 37 °C for
10 min. In certain cases, inhibitors were added and cells were incubated at 37 °C for 10
min prior to stimulation. Reactions were stopped by addition of equal volume 2%
paraformaldehyde and 0.1 mM EDTA followed by centrifugation at 10,000 g for 5 min.
[3H] counts were measured from the supernatants of stimulated samples and
unstimulated controls, which were used as background. To determine total loading, [3H]
counts were measured in an equal volume of loaded cells following lysis in an equal
volume of fixing buffer plus 2% Triton X-100. Percent serotonin release was represented
as ([3H] sample – [3H] background) / ([3H] total – [3H] background) x 100. Percent
inhibition was represented as (% release with inhibitor) / (% release without inhibitor) x
100.
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Thrombocyte aggregation assays
Thrombocyte-rich plasma collected from blood anticoagulated in sodium citrate was
diluted to a concentration of 2 x 107 cells per mL. 5 x 106 cells were used for each
stimulation. Aggregation assays were performed as previously described58.

Preparation of chicken collagen-coated slides
An acid-soluble chicken collagen types-I and –III prep was prepared as described
previously154. Reconstitution of fibrilar chicken collagen was performed as previously
indicated155. Briefly, the collagen was dissolved in 0.5 M acetic acid at 1.5 mg/mL and
dialyzed against 2 changes of 50 mM Tris HCl, pH 7.5 at 4 °C over 48 h. After dialysis,
the gelatinous white collagen precipitate was resuspended with a repeated aspiration
through a 22-gauge needle and then sonicated with a steel probe sonicator (Branson 450
Digital Sonifer®, Danbury, CT) on ice for 3 pulses of 5 sec at 10% amplitude with at
least 15 sec between pulses. Coating of microscope slides was performed as described
previously 40. Briefly, 300 µL of fribrillar chicken collagen was placed in a flexiperm
well that was attached to an EtOH-washed 25 x 75 mm glass (Fisher, Pittsburgh, PA) or
PermanoxTM (Nunc, Rochester, NY) microscope slide, for scanning electron microscopy
assays, and incubated at 4 °C overnight. Slides were then washed 2 times with PBS and
blocked with 1% denatured BSA for at least 1 h at room temperature prior to use.
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Whole blood flow assays
The tapered-wall parallel plate flow chamber was assembled as previously described40,156.
The assembled chamber was then placed on the stage of an inverted microscope (Nikon
Eclipse TE2000-U, Melville, NY). Blood collected in PPACK was warmed at 37 °C for
10 min, along with inhibitors, and 2.5 µg/mL fluorescently labeled Alexa-Fluor 488conjugated AP-2 mAb was added, which binds both human and chicken #2b$3 to label
platelets or thrombocytes123. Whole blood was perfused over the collagen-coated glass
slide at a flow rate of 0.428 mL/min using a syringe pump (Model ‘11’ Plus; Harvard
Apparatus) for 5 min. After whole blood perfusion, chambers were rinsed with modified
Tyrode’s buffer at the same flow rate for 5 min prior to static image collection.

Whole blood flow image capture and analysis
During whole blood flow, platelet or thrombocyte adhesion was monitored continuously
by epifluorescence microscopy. Images were captured using a CCD camera (C9300-201
Hamamatsu, Bridgewater, NJ) mounted on an inverted microscope with a 300 W Xenon
lamp (Perkin Elmer Optoelectronics, Freemont, CA) through a Lambda DG-4 high-speed
filter changer (Sutter Instruments, Novato, CA) used at 470 nm Ex / 525 nm Em. For
real-time fluorescent microscopy during blood flow, images were captured continuously
with a 300 ms exposure time at an interval of 100 ms using Slidebook software
(Intelligent Imaging Innovations) as previously described153. Static image collection was
obtained using epifluorescence microscopy at different axial positions along the flow
chamber that correspond to a given shear rate. Platelet or thrombocyte percent surface
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coverage and average aggregate size were quantified using ImageG software (National
Institutes of Health). Both results were reported as the mean plus or minus standard error
of the mean (SEM).

Fluorescent microscopy of collagen slides following whole blood flow
Slides were removed from the flow chamber and fixed in 1% paraformaldehyde for 5 min
and washed 3 times in PBS. Slides were then permeabilized in 0.02% Triton X-100 in
PBS with BSA 1 mg/mL for 5 min followed by 3 washes in PBS. Filamentous actin was
stained with Alexa-Fluor 594-conjugated phalloidin (25 µL/mL) for 45 min at room
temperature. Slides were imaged with fluorescent microscopy as previously described99.

Scanning electron microscopy of collagen slides following whole blood flow
Permanox™ (Thermo Fisher Scientific, Rochester, NY) slides were coated with chicken
collagen as described for glass slides. Permanox was used to facilitate slide cutting for
microscopy preparation. Following whole blood perfusion, slides were removed from the
flow chamber, washed 3 times in PBS, and fixed in 2% glutaraldehyde until microscopy
analysis. Slide sections were analyzed on a Philips XL20 scanning electron microscope.

Flow cytometric analysis
Washed platelets or thrombocytes were diluted to a concentration of 2.5 x 107 platelets
per mL or 2 x 107 cells per mL, respectively, and 2.5 x 106 platelets or 2.5 x 106
thrombocytes were stained with Alexa-Fluor 488-conjugated AP-2 mAb at room
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temperature for 1 h and analyzed by flow cytometry. Mean fluorescent intensity of AP2-positive cells was quantified for platelets and thrombocytes.

Thrombocyte spreading assay
Lab-Tek II chamber slides (Thermo Fischer Scientific, Rochester, NY) were coated with
type I fibrillar collagen (Chronolog) at 30 µg/mL in 50 µM acetic acid for 16 h at 4 °C,
washed 3 times with PBS, and blocked with BSA 1 mg/mL in PBS for 30 min at room
temperature. Thrombocyte-rich plasma was diluted to 2 x 107 cells per mL in modified
Tyrode’s buffer containing 1 mM MgCl2 and 1 mM CaCl2, and 500 µL of cells were
incubated on the collagen-coated chambers for 45 min at 37°C. Fixation, permeablizing,
and staining were performed as previously reported153.
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Figure 3-1. Analysis of chicken plasma preps by flow cytometry.
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Figure 3-1. Analysis of chicken plasma preps by flow cytometry. A. Washed chicken
thrombocyte-rich plasma was stained with Alexa-Fluor 488-conjugated AP-2 mAb and
analyzed by flow cytometry. Thrombocytes could be detected at a distinct forward and
side scatter from leukocytes (compare gate 1 to gate 2) and were readily identified by
expression of the thrombocyte-specific marker #2b$3 (AP-2-positive cells).
B. Thrombocyte-rich plasma cells were sorted for transcriptional profiling based on
positive and negative selection markers using the lymphocyte-specific mAb K55, which
excludes thrombocytes, and the thrombocyte-specific mAb AP-2. Gate 1 was specific for
lymphocytes while gate 2 was specific for thrombocytes.
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Table 3-I. Detection of platelet-specific gene expression in thrombocytes by
transcriptional profiling.

Gene
MPL
GP9
ITGB3
ITGB1
ITGA6
ITGA2
ITGAV
PAR1
PAR4
P2RX1
P2RY1
HTR2A
CD36
TBXAS1

Ratio (T/L)
422.0
892.4
612.8
2.2
5.2
215
24.3
26.3
7.0
823.7
15.0
467.1
1027.5
74.8

Fold Change
821.2
6.7
597.6
1.07
1.02
9.5
1.36
1.005
38.2
29.0
209.4
4.03
42.5

P value
3.5E-05
3.8E-04
5.3E-05
0.002
0.004
1.3E-06
3.1E-04
0.001
0.007
2.0E-04
2.2E-04
1.0E-04
5.0E-04
2.0E-04

Table 3-I. Detection of platelet-specific gene expression in thrombocytes by
transcriptional profiling. Thrombocytes and lymphocytes were sorted by positive and
negative selection for cell-specific markers, and gene expression analysis was performed
using the Affymetrix chicken gene chip. The gene expression ratio of thrombocytes to
lymphocytes (T/L), fold change, and P values for genes of known platelet specificity
present in the chicken chip are shown.
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Figure 3-2. Activation of chicken thrombocytes by collagen and thrombin.
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Figure 3-2 (cont’d). Activation of chicken thrombocytes by collagen and thrombin.

D
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Figure 3-2. Activation of chicken thrombocytes by collagen and thrombin. 5-HT
release from platelets or thrombocytes was measured following loading with [3H] 5-HT.
Cells were stimulated with increasing doses of bovine thrombin (A) or equine type-I
collagen (B) or various agonists (C). In panel C, thrombin, collagen, and ADP were used
at concentrations of 1 U/mL, 3.0 µg/mL, and 10 µM, respectively. D. Aggregation of
chicken thrombocytes in response to various agonists. Thrombocyte-rich chicken plasma
was stimulated with indicated agonists, and aggregation was measured by percent light
transmittance in a luri-aggregometer.
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Figure 3-3. PP2 and piceatannol inhibit collagen-induced 5-HT secretion in
thrombocytes in a dose-dependent manner.
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Figure 3-3. PP2 and piceatannol inhibit collagen-induced 5-HT secretion in
thrombocytes in a dose-dependent manner.
5-HT release from platelets or thrombocytes was measured following loading with [3H]5-HT. Chicken thrombocytes were stimulated with either thrombin (1 U/mL) or collagen
(3 µg/mL) in the presence of increasing doses of PP2 (A) or piceatannol (B). C. PP2 (3
µM ) and piceatannol (30 µM) were used to inhibit 1 U/mL thrombin- or 3.0 µg/mL
collagen-induced 5-HT release in either human platelets or chicken thrombocytes. In all
panels, shown is the mean ± SD; n = 3 experiments per condition.
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Figure 3-4. Chicken collagen type-I and –III coated on glass slides.

Figure 3-4. Chicken collagen type-I and –III coated on glass slides. Chicken collagen
type-I and –III was purified from chicken skin and dialyzed against 0.05 M Tris-HCl pH
7.5 to create a fibrillar peptide. A. Chicken collagen was coated on glass slides overnight
at 4 ºC. B. Glass slides coated with Chronolog type-I equine collagen are shown for
comparison.
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Figure 3-5. Thrombocytes cover less surface area and fail to form aggregates
during adhesion to collagen under whole blood flow.
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Figure 3-5 (cont’d). Thrombocytes cover less surface area and fail to form
aggregates during adhesion to collagen under whole blood flow.
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Figure 3-5. Thrombocytes cover less surface area and fail to form aggregates
during adhesion to collagen under whole blood flow. PPACK-anticoagulated human
or chicken whole blood was labeled with AP-2 mAb and perfused through a tapered-wall
parallel plate flow chamber for 5 min over a chicken collagen-coated glass slide.
A. Time traces of percent surface coverage of collagen surface by platelets or
thrombocytes. Shown is mean ± SD; n = 7-10 for each condition. B. Representative
fluorescent images captured at areas corresponding to shear rates of 1300, 1100, 700, and
400 s-1 after 5 min perfusion of whole blood. C. Representative images of thrombocyte
or platelet adhesion to collagen following whole blood flow for 5 min at 1300 s-1. Slides
were fixed, permeabilized, and stained with Alex-Fluor 594-conjugated phalloidin to
detect actin filaments. Nuclear staining of thrombocytes with DAPI is also shown.
D. Percent collagen surface area coverage (i) and mean aggregate area (ii) of human
platelets or chicken thrombocytes following perfusion of whole blood for 5 min was
determined by analysis of fluorescent images. Shown are the mean ± SEM; n = 7-10
experiments for each condition.
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Figure 3-6. Chicken thrombocytes do not form aggregates after extended flow of
whole blood.

Figure 3-6. Chicken thrombocytes do not form aggregates after extended flow of
whole blood. A. Representative fluorescent images captured at areas corresponding to
shear rates of 1300, 1100, 700, and 400 s-1 after 15 min perfusion of chicken whole
blood. B. Representative images of thrombocyte adhesion to collagen following whole
blood flow for 15 min at 1300 s-1. Slides were fixed, permeabilized, and stained with
phalloidin and DAPI. Note that each adherent thrombocyte can be distinctly visualized
by DAPI staining, demonstrating an absence of 3-dimensional aggregation.
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Figure 3-7. Scanning electron microscopy of platelets and thrombocytes following
adhesion to collagen under whole blood flow.
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Figure 3-7. Scanning electron microscopy of platelets and thrombocytes following
adhesion to collagen under whole blood flow. PPACK-anticoagulated human or
chicken whole blood was perfused through a tapered-wall parallel plate flow chamber for
5 min over a chicken collagen-coated slide. Images were obtained by scanning electron
microscopy at regions corresponding to a shear rate of approximately 1300 s-1. Platelets
and thrombocytes were imaged at magnifications of 650 X (A), 2000X (B), and 8000 X
(C). D. The inside of a platelet aggregate imaged at 10,000 X. E. Adherent
thrombocytes forming membrane contacts at 3500 X.
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Figure 3-8. Thrombocyte adhesion to collagen under flow is sensitive to Src-family
kinase inhibition.

Figure 3-8. Thrombocyte adhesion to collagen under flow is sensitive to Src-family
kinase inhibition. A. Percent collagen surface area coverage of platelets (i) or
thrombocytes (ii) following perfusion of 5 mM EDTA-treated whole blood for 5 min was
determined by analysis of fluorescent images. B. Percent collagen surface area coverage
of human platelets (i) or chicken thrombocytes (ii) following perfusion of 10 µM PP2treated whole blood for 5 min. Shown are the mean ± SEM; n = 4 experiments for each
condition.
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Figure 3-9. Thrombocytes express fewer # 2b$ 3 integrin receptors than do platelets
and are not affected by # 2b$ 3 inhibition during adhesion to collagen under flow.
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Figure 3-9. Thrombocytes express fewer # 2b$ 3 integrin receptors than do platelets
and are not affected by # 2b$ 3 inhibition during adhesion to collagen under flow.
A. Levels of #2b$3 integrin expression on washed human platelets and washed chicken
thrombocyte-rich plasma were determined by staining with AP-2 mAb and analyzed by
flow cytometry. i. Representative staining of human platelets and chicken thrombocytes
for the #2b$3 integrin, as determined by AP-2 mAb binding. Gates denote regions
analyzed, and only AP-2 positive cells were analyzed for mean fluorescence intensity
(MFI). ii. The histogram depicts MFI of AP-2 binding ± SD.
B. Eptifibatide inhibits chicken thrombocytes aggregation. Thrombocytes were
stimulated with 1 µg/mL collagen in the presence or absence of 10 µM eptifibatide, and
aggregation was measured by percent light transmittance in a luri-aggregometer.
C. Percent collagen surface area coverage of human platelets (i) or chicken thrombocytes
(ii) following perfusion of 10 µM eptifibatide-treated whole blood for 5 min was
determined by analysis of fluorescent images. D. Mean platelet aggregate area following
perfusion of 10 µM eptifibatide-treated whole blood for 5 min. For panels C and D,
shown are the mean ± SEM; n = 4 experiments for each condition.
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Figure 3-10. The effect of P2Y12 inhibition on platelet and thrombocyte adhesion to
collagen under flow.

Figure 3-10. The effect of P2Y12 inhibition on platelet and thrombocyte adhesion to
collagen under flow. A. MesAMP inhibits thrombocyte aggregation. Thrombocytes
were stimulated with 100 µM in the presence or absence of 75 µM MesAMP, and
aggregation was measured by percent light transmittance in a luri-aggregometer. Percent
collagen surface area coverage of human platelets (B) or chicken thrombocytes (C)
following perfusion of 75 µM MesAMP-treated whole blood for 5 min was determined
by analysis of fluorescent images. Shown are the mean ± SEM; n = 4 experiments for
each condition.
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Supplemental movie legends
For all movies, PPACK-anticoagulated human or chicken whole blood was labeled with
AP-2 mAb and perfused through a tapered-wall parallel plate flow chamber for 5 min
over a chicken collagen-coated glass slide. Each movie depicts cell adhesion at a shear
rate of 1200 s-1.
Supplemental movie 3-1. Adhesion of human platelets following perfusion of whole
blood over chicken collagen.

Supplemental movie 3-2. Adhesion of chicken thrombocytes following perfusion of
whole blood over chicken collagen.

Supplemental movie 3-3. Adhesion of human platelets following treatment with 30
µM PP2 and perfusion of whole blood over chicken collagen.

Supplemental movie 3-4. Adhesion of chicken thrombocytes following treatment
with 30 µM PP2 and perfusion of whole blood over chicken collagen.

Supplemental movie 3-5. Adhesion of human platelets following treatment with 75
µM eptifibatide and perfusion of whole blood over chicken collagen.

Supplemental movie 3-6. Adhesion of chicken thrombocytes following treatment
with 75 µM eptifibatide and perfusion of whole blood over chicken collagen.
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Chapter 4—Conclusions and future directions

Summary
Collagen-induced activation of platelets is believed to be a primary step in platelet
function during physiologic hemostasis and pathologic thrombosis. The immune-type
receptor GPVI is a platelet-specific receptor required for collagen-induced activation. In
Chapter 2, we demonstrate that the GPVI receptor contains a proline-rich domain, unique
to GPVI compared to other homologous receptors, that constitutively binds and directly
activates the Src-family kinase Lyn. The interaction of GPVI and Lyn via the prolinerich domain accelerates GPVI signaling kinetics and is required for efficient platelet
adhesion to collagen under flow. In Chapter 3, we characterize the collagen response of
the chicken thrombocyte, which expresses platelet-specific receptor orthologs but does
not contain GPVI. Thrombocytes are capable of activating in response to collagen, using
a signaling pathway analogous to that of GPVI, and they adhere to collagen under high
shear. However, thrombocytes express a significantly lower level of #2b$3 integrin than
do platelets, and they do not form 3-dimensional aggregates under flow conditions. Our
studies demonstrate fundamental conservation of responses to collagen by hemostatic
cells but suggest that platelets have adapted additional mechanisms to promote
aggregation under high shear conditions. Moreover, our findings raise new questions
about GPVI signaling and thrombocyte function in hemostasis.
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Use of immune-type receptor signaling to activate hemostatic cells in response to
collagen
GPVI is well characterized as a platelet-activating receptor that uses an immune tyrosine
kinase pathway to activate platelets. Most other activating receptors on platelets are G
protein-coupled and use a fundamentally different signaling pathway. A potential, albeit
simplified, explanation for why an immune signaling response to collagen may be
advantageous compared to a G protein-coupled response is the fact that signaling via
receptor clustering (immune-type receptors, driven by avidity) rather than conformational
change (G protein-coupled receptors, driven by receptor-ligand affinity) allows for a
graded and sustained signaling response. As the major component of the subendothelial
matrix, collagen, exposed following vessel injury, may be the first ligand encountered by
the platelet. Use of an immune receptor signaling pathway allows platelet activation to
be modulated depending on the degree of collagen exposure. The response of platelets to
collagen may be excessive in pathological situations where the balance shifts from
hemostatic platelet activation to pathological thrombosis. Nevertheless, our findings in
Chapter 2 show that the classical mechanism of immune receptor signaling employed by
B-cells and T-cells has been modified by platelet GPVI to suit the unique context of
collagen-induced activation under hemodynamic flow.
The fact that GPVI contains a proline-rich domain that constitutively binds and
directly activates Lyn means that the receptor is primed for rapid activation following
ligand binding. This molecular priming allows GPVI to function more effectively under
arterial shear, where the platelet only has seconds to activate and firmly adhere. While
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this adaption of GPVI increases platelet responses to collagen under flow, it is not
absolutely essential for this response. Proline-rich domain-deleted GPVI platelets still
adhere to collagen more effectively that GPVI-deficient platelets. It is unknown whether
the collagen receptor(s) on thrombocytes employ a proline-rich domain to accelerate
signal transduction. It could be difficult and misleading to calculate a relative adhesive
efficiency for platelets compared to thrombocytes, but thrombocytes do not seem to be
defective in transitioning from the rolling phase to the firmly adherent phase.
Thrombocytes, like platelets, are clearly engineered for shear resistant adhesion to
collagen under flow, and this behavior is equally sensitive to Src-family kinase inhibition
in both cell types. Therefore, the initial response to collagen, in both signal transduction
and adhesion under flow, appears conserved between platelets and thrombocytes. The
fundamental difference between platelets and thrombocytes seems to lie outside of their
relative responses to collagen and relates more significantly to their basic mechanisms
promoting aggregate formation under high shear.

Future directions for GPVI and thrombocyte research
Our observations provide insight into the molecular function of GPVI in platelet biology
and characterize the response of a more primitive hemostatic cell—the thrombocyte—
during adhesion to collagen under whole blood flow. Our results uncover new questions
that require future investigation.
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Is GPVI / FcR! embedded in the cell membrane to prevent constitutive signaling from
bound and activated Lyn kinase?
Our findings in Chapter 2 suggest that GPVI keeps Lyn constitutively bound and held in
an active state. We propose that, in order to prevent the undesirable effects of constitutive
signaling through the GPVI / FcR! complex, the GPVI cytoplasmic tail and/or the FcR!
chain is embedded in the platelet membrane, keeping the GPVI-bound Lyn and the FcR!
ITAM at a suitable distance from one another to prevent activation prior to receptor
ligation. Xu et al. have demonstrated that the membrane-proximal basic residues on the
CD3& chain of the T-cell receptor mediate binding to the cell membrane and keep the
CD3& ITAM embedded in the lipid bilayer112. Both GPVI and FcR! have an enrichment
of positively charged amino acids on the proximal end of their cytoplasmic tails. We
believe GPVI / FcR! is an excellent model to test the functional requirements of these
membrane-proximal basic residues in preventing constitutive GPVI signaling. GPVI is
an extreme example of an immune-type receptor that exists in a tightly coupled off-on
state due to its identity as a hemostatic receptor primed to mediate rapid cellular
activation following receptor ligation.
Future studies aimed at determining whether the GPVI cytoplasmic tail and/or the
FcR! chain are embedded in the membrane should be performed using a fluorescence
resonance energy transfer (FRET) approach in lipid micelles, similar to that employed by
Xu et al. Membrane proximal basic residues in GPVI and FcR! can be mutated to
determine if they are required to prevent constitutive signaling through GPVI in the
absence of receptor ligation. Use of retroviral complementation to express membrane
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proximal mutants in GPVI-deficient bone marrow will be a useful strategy to determine
the importance of these residues in GPVI surface expression and signaling in the platelet.

What are the selective roles of Lyn and Fyn kinase in the initial events of GPVI
signaling?
Our findings in Chapter 2 are consistent with a model in which Lyn kinase is
constitutively bound to GPVI and held in an activated state, primed to mediate immediate
signaling following receptor ligation. However, Fyn co-immunoprecipitates with the
GPVI / FcR! signaling complex following receptor stimulation, and absence of Fyn
confers a decrease in GPVI-induced platelet activation (see Chapter 2)47. Our studies
support a model in which Lyn drives initial GPVI signaling, whereas Fyn is responsible
for sustained GPVI signaling required for potentiating GPVI-induced platelet activation.
What are the mechanisms that underlie this division of labor for the Src-kinases Fyn and
Lyn in GPVI signaling? Our studies using a phage display suggest that Fyn does not
have a high affinity for the GPVI proline-rich domain. However, our biochemical studies
and those of others have demonstrated that both Lyn and Fyn can associate with the
GPVI proline-rich domain or perhaps with other members of the GPVI signaling complex
(see Chapter 2)95.
Specific investigation should focus on the relative affinities of Lyn and Fyn for
GPVI and determining whether Fyn and Lyn associate with other members of the GPVI
signaling complex, such as Syk, Slp-76, LAT, or PLC!2. We predict that association of
Fyn with GPVI or other signaling effectors may be facilitated through ligand-induced
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GPVI clustering, and this mechanism should be investigated more thoroughly. At an
organism level, genetic experiments in collagen-dependent injury models using Fyn- and
Lyn-deficient animals can determine if Lyn is selectively required for initial thrombus
formation and Fyn is required for thrombus stability. Such studies would refine our
knowledge of downstream signaling events following GPVI stimulation by determining
distinct roles for Fyn and Lyn in collagen-induced thrombus formation.

What is the receptor responsible for activating thrombocytes in response to collagen?
The fact that GPVI is a low-affinity receptor for collagen requires that alternative ligands
other than native collagen had to be used to molecularly identify this platelet collagen
receptor. The identification of GPVI was aided by the fact that patient autoantibodies
against GPVI and the snake venom toxin convulxin could serve as high-affinity ligands
for use in biochemical assays157,158. Identification of the thrombocyte collagen receptor is
of interest because its lack of binding convulxin and CRP suggests it is structurally
different from GPVI and may interact with collagen differently. Our findings in Chapter
3 suggest that the chicken thrombocyte collagen receptor uses an immunotyrosine kinase
pathway dependent on Syk and Src-family kinases analogous to that of GPVI. Methods
to isolate the thrombocyte collagen receptor could employ a Syk tandem SH2 domain
GST fusion protein to pull down the receptor-ITAM adaptor complex for protein
analysis. Identification of this receptor would provide further insight into the adaptation
of immune receptors for collagen binding and signal transduction in hemostatic cells.

141

How is GPVI function conserved among mammalian species?
The observation that chicken thrombocytes are activated by fibrillar collagen implies that
collagen-induced activation of hemostatic cells has been conserved throughout evolution.
It is intriguing that collagen signaling in both thrombocytes and platelets is sensitive to
inhibition of Src-family kinases and Syk. This finding suggests that the use of immune
receptor signaling pathways to activate hemostatic cells in response to collagen has also
been conserved—perhaps because the nature of immune receptor signaling allows for a
graded response that is desirable for collagen-induced hemostatic activation. It is
impossible to know if mammalian GPVI evolved from collagen-sensing immune
receptors found in more primitive species. However, the fact that GPVI is not detectable
in the platypus genome suggests that GPVI evolved after true non-nucleated platelets
came be to utilized as dedicated hemostatic cells. If this is correct, then a lack of
response to GPVI-agonists should be observed in platelets from monotreme species but
not in platelets from marsupials, the species most evolutionarily distant from placental
mammals that have a GPVI ortholog.
To test whether monotreme or marsupial platelets respond to GPVI agonists, we
obtained platelet samples from an echidna (spiny anteater), a monotreme, and a striped
opossum (a marsupial). While we would expect collagen-induced activation to be
conserved in all these species, as they are conserved in more primitive thrombocytes, the
ability to respond to GPVI-specific agonists like CRP is of interest because the echidna
represents a “missing link”—a species that has platelets but does not express GPVI.
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We have performed one set of preliminary experiments, and the results are
somewhat consistent with gene ontology data suggesting that monotremes lack GPVI,
while marsupials possess GPVI. Platelets from the echidna did not activate in response
to convulxin, as demonstrated by a lack of spreading on a convulxin-coated surface and a
lack of fibrinogen binding in response to convulxin (Fig. 4-1). In comparison, platelets
from the opossum, a marsupial, spread on convulxin and bound fibrinogen in response to
convulxin stimulation (Fig. 4-1). These data support results from genetic database
searches that indicate the presence of a GPVI ortholog in marsupial, but not monotreme,
species. Importantly, echidna, opossum, and mouse platelets all bind fibrinogen in
response to ADP stimulation, suggesting that robust ADP-induced platelet activation is
conserved and distinguishes platelet responses from those of thrombocytes. To date, it is
unknown if thrombocytes are direct ancestors of mammalian platelets or if platelets
evolved separately. Echidna platelets did not readily adhere to CRP, but those that did
demonstrated spreading (Fig. 4-1A). The significance of this finding is unknown, but it
is possible that there are subset populations among echidna platelets that may express
receptors capable of interacting with CRP (Fig. 4-1B).
Interestingly, opossum platelets were not strongly activated by CRP, evidenced by
only weak fibrinogen binding and a lack of robust spreading response (Fig. 4-1). This
finding is difficult to reconcile with the identity of a true GPVI ortholog in the opossum,
but it should be mentioned that the GPVI ectodomain region responsible for collagen
interaction is only partially conserved from opossum to mouse to human (Fig 4-2). Key
residues that have been implied in collagen and/or CRP binding are not present in
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opossum GPVI, and the 11 amino acid deletion between GPVI and Fc#RI that creates a
collagen-binding apical groove in GPVI is only a 5 amino-acid deletion in opossum
GPVI (Fig 4-2). Additionally, opossum GPVI contains an extracellular stalk that is 31
residues longer than that of human or mouse GPVI and is poorly conserved. It is difficult
to speculate on the significance of these differences, but it is possible that the
fundamental nature of the GPVI-collagen interaction has not been highly conserved in
mammalian species and has undergone continued evolution. This lack of conservation is
in contrast with the highly conserved cytoplasmic proline-rich domain studied in Chapter
2 and supports the characterization of GPVI as a collagen sensor selected through
evolution for its signal transduction rather than its collagen binding properties. However,
it is known that human GPVI has a higher affinity for CRP than does mouse GPVI159.
The fact that opossum GPVI has little or no ability to be activated by CRP suggests that
improving affinity for the GPO repeats constituting a fraction of the native collagen
peptide may have increased the sensitivity of GPVI as a hemostatic collagen receptor.

If thrombocytes do not form aggregates on collagen under arterial flow conditions, how
does cellular hemostasis function in avian species?
The use of flow chambers to model platelet adhesion to collagen under arterial shear
conditions reproduces a fundamental aspect of platelet biology—the formation of a
platelet-driven thrombus in both in vivo injury models in the mouse arterial system and in
human coronary thrombosis following atherosclerotic plaque rupture. The fact that
chicken thrombocytes do not form aggregates in the flow chamber system, whereas
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platelets do, raises the question of how thrombocytes respond in vivo following arterial
injury. Do injuries to bird arteries equivalent to those used in mouse injury models result
in an occlusive thrombus? Are thrombocytes capable of forming aggregates in highpressure vessels following exposure of ECM components? Alternatively, are there
additional factors present in vivo that are not reproduced in flow chamber models that
allow for shear-resistant aggregate formation? We hypothesize that cellular thrombus
formation under arterial shear in vivo is a platelet-specific, and therefore mammalianspecific, phenomenon.
In order to answer these questions, an arterial injury model needs to be developed
for avian species. We are working on establishing a model where we can isolate a bird
carotid artery that is equivalent in size to that of a mouse carotid and use FeCl3 to injure
endothelial cells and expose subendothelial collagen69. This injury model reproducibly
generates a platelet-driven occlusive thrombus in wild-type mice. A doppler flow probe
will be used to determine the presence of, and time to, occlusion following FeCl3 injury.
We will also take vessel specimens for histology following injury to determine the
thrombocyte response following application of FeCl3. Identical experiments on wild-type
mouse carotids will be performed as controls. We predict three possible results, all of
which would be informative: (1) the avian carotid artery does not occlude following
injury, consistent with the ability of thrombocytes to form a monolayer on collagen under
arterial flow but not form 3-dimensional aggregates; (2) the avian carotid does occlude,
but utilizes a more robust coagulation response to form a thrombocyte-poor thrombus; (3)
the avian carotid occludes via a thrombocyte-rich thrombus, suggesting that mechanisms
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not represented in the flow chamber, such as the contribution of thrombin or other
agonists, are required for thrombocyte-mediated thrombosis.
These studies will determine if the ability of hemostatic cells to form occlusive
thrombi in vivo is unique to mammals. The results of this work can provide insight into
the evolutionary adaptations of the response to traumatic injury. These studies will also
address whether, by acquiring the ability for shear-resistant aggregation, the presence of
platelets, rather than thrombocytes, fundamentally predisposes humans to cardiovascular
morbidity and mortality.

Concluding remarks: The evolution of platelet responses to collagen under
conditions of hemodynamic flow
Fibrillar collagen is the major component of the subendothelial ECM and serves as both
an adhesive surface and activating stimulus for platelets in the circulation. In multiple
ways, platelets are uniquely engineered to arrest their flow, activate, and aggregate under
the high shear conditions of the arterial system. Essential elements that mediate the
function of platelets in hemostasis and pathological thrombosis include: the small size of
the platelet; high platelet numbers in blood; robust signaling in response to several
endogenous agonists; dynamic cell spreading behavior; and a high density of #2b$3 to
allow aggregation.
Our studies began with a focus on the collagen receptor GPVI, where we
discovered a novel mechanism of direct Src-family kinase activation by the GPVI
proline-rich domain that accelerates GPVI signaling to allow for more efficient platelet

146

activation in response to collagen under whole blood flow. The fact that this proline-rich
region is highly conserved among all known GPVI receptors implies an importance for
this domain in mediating collagen signaling in platelet biology. This finding prompted us
to investigate the response to collagen of thrombocytes, which do not contain a GPVI
ortholog. Our results, however, demonstrated that, even in the absence of GPVI,
thrombocytes contain a receptor capable of robust collagen-induced activation and
adhesion under flow. Our focus shifted away from the collagen-GPVI axis and
concentrated instead on the remarkable finding that chicken thrombocytes do not form
aggregates under shear conditions. Compared to any differences in the collagen receptor,
the fact that thrombocytes contain a 10- to 20-fold lower density of #2b$3 on the cell
surface could account for their profound difference in behavior under hemodynamic flow
conditions. To augment their aggregation response, platelets utilize positive feedback
through an array of secondary agonists (ADP, thromboxane, and 5-HT), to which
thrombocytes also lack a robust response. Whether increased #2b$3 density, and
therefore shear-resistant aggregation, preceded or co-evolved with the ability of platelets
to maintain activation through secondary agonists is unknown.
The use of thrombocyte studies in zebrafish models has grown in popularity,
based on the ease of genetic manipulation and relatively high-throughput whole organism
hemostasis and thrombosis assays144,160. Based on our findings, we would caution against
the assumption that thrombocyte function in primitive vertebrates is completely
analogous to platelet function in mammals. The evolution of platelet responses to
collagen under hemodynamic flow is most profoundly characterized by the response of
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platelets after collagen-induced activation—aggregation and potentiation through
secondary agonists. GPVI, which appears in evolution after the emergence of true
platelets in primitive mammals, may represent the evolutionary fine-tuning of the robust
collagen signaling that is inherent in all hemostatic cells. This fine-tuning may have been
advantageous or even essential for mammalian survival following acute trauma, yet
predisposes humans with atherosclerotic lesions to coronary and cerebrovascular
occlusion.
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Materials and methods
Isolation of platelets from echidna and opossum
Juvenile echidna and striped opossum studies were performed under supervision from the
veterinarian staff at the Philadelphia Zoo. A juvenile echidna and striped opossum were
anesthetized using isofluorine inhalation. Blood samples were collected from intra-nasal
capillary beds into a syringe containing 15 U/mL heparin. Platelet-rich plasma was
obtained by centrifugation of whole blood following dilution into 1:2 blood:Tyrode’s
buffer, as indicated in Chapter 2. All platelet function studies were performed as
described in Chapter 2.
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Figure 4-1. The response of echidna and opossum platelets to GPVI ligands.
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Figure 4-1 (cont’d). The response of echidna and opossum platelets to GPVI
ligands.
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Figure 4-1. The response of echidna and opossum platelets to GPVI ligands.
A. Platelets from echidna, opossum, or mouse blood were allowed to spread on glass
slides coated with fibrinogen, CRP, or convulxin. Platelets were fixed, permeabilized,
and stained with Alexa-Fluor 594-conjugated phalloidin to detect actin filaments.
B. Stimulation of echidna, opossum, or mouse platelets with GPVI agonists. Platelets
were stimulated with ADP, CRP, or convulxin for 10 min, and platelet activation was
measured by the degree of fibrinogen binding, detected by flow cytometry. For echidna
platelets, a subset of platelets could be detected (gate 2) that bound fibrinogen in response
to CRP stimulation.
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Figure 4-2. Alignment of GPVI sequences from opossum, mouse, and human.
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Figure 4-2. Alignment of GPVI sequences from opossum, mouse, and human.
Amino acid residues implied in collagen or CRP binding are outlined in black, and
conserved residues are shown in red text. Residues of similar charge or non-conserved
residues are shown in blue and orange text, respectively. Polar residues believed to lie at
the edge of the collagen-binding groove of GPVI are outlined in green. Hydrophobic
residues believed to form the floor of the GPVI collagen binding groove are outlined in
brown. Note the absence of many residues involved in collagen binding or formation of
the collagen-binding groove in opossum GPVI. Also, note the absence a 6-residue
deletion in opossum GPVI compared to mouse or human GPVI that is believed to form
the collagen-binding groove.
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